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Abstract 
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is responsible 
for approximately 1.5 million deaths worldwide; a pandemic which is further exacerbated by 
the emergence of multi- and extensively drug resistant strains. The extensive morbidity and 
mortality associated with TB has brought about an urgent need for new drugs that promise to 
shorten treatment duration and reduce the daily pill burden. In this context, the mycobacterial 
cell wall, particularly the peptidoglycan (PG) layer, is a promising source of new drug targets 
due to the extensive number of bacterial-specific enzymes that are responsible for 
biosynthesis of this macromolecular component in bacterial cells. PG biosynthesis and cross-
linking involves a number of membrane-bound as well as cytoplasmic enzymes, including 
penicillin-binding proteins (PBPs), which are the targets for beta-lactam antibiotics. In this 
study we further elucidate the role of DD-Carboxypeptidases (DD-CPases), a group of low 
molecular mass PBPs that play a crucial role in the biosynthesis and remodelling of PG in a 
variety of organisms. These enzymes cleave the terminal D-Alanine residue in PG and are 
postulated to be involved in preventing the formation of inappropriate cross-links. To identify 
possible interacting partners for two of the five putative DD-CPases (DacB and 
MSMEG_2433) in Mycobacterium smegmatis, a full-coverage, representative genomic 
library was constructed as fusions with the Gal4 DNA binding domain in a yeast two-hybrid 
vector. The genes encoding dacB and MSMEG_2433 were cloned as fusions with the Gal4 
activation domain and these clones were used to screen the library for putative interacting 
partners. This analysis identified fifteen possible interacting partners in total for these two 
DD-CPases. DacB interacting proteins included a tetracycline regulator, an acyltransferase, as 
well as a subunit of the FoF1 ATP synthase. Putative interacting proteins identified for 
MSMEG_2433 included the same tetracycline regulator that was identified for DacB, a 
helicase, and PBP1A/1B (PonA2). PonA2 is of particular interest as its identification points 
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to a role for DacB in PG cross-linking. For cellular localization studies, C-terminal fusions 
with the mCherry; Venus and rsEGFP fluorescent proteins were created for DacB and 
MSMEG_2433. Fluorescence microscopy revealed weak or diffused signal from the mCherry 
and Venus fusion proteins, in contrast, the rsEGFP fusion yielded specific, robust signal and 
was used for further analysis.  Localization studies revealed that both DacB and 
MSMEG_2433 localized to the cell pole either in a mono-polar or bi-polar fashion similar to 
that observed with other cell division proteins such as Wag31 and ParB. Furthermore, 
MSMEG_2433 also localized to the septum in some cases. Collectively, the data from this 
study suggests that DD-CPases may interact with other PG hydrolysing enzymes to exert their 
function in mycobacteria. Moreover, localization confirms an important role for these 
enzymes in cell growth and expansion, which occurs at cell poles in mycobacteria.   
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1. Introduction 
1.1. Background 
“Among all infectious diseases that afflict humans, Tuberculosis (TB) remains the deadliest,” 
(Ducati et al., 2006). 
According to the 2013 report by the World Health Organisation (WHO), 8.6 million new and 
recurring cases of TB were reported, of which 1.3 million cases resulted in death and 1.1 
million were HIV positive  (WHO, 2013). TB was previously described as consumption since 
following transmission, primarily by aerosolized droplets expectorated by infected persons, 
there is drastic weight loss, night sweats, as well as a violent cough (Glickman and Jacobs, 
2001). The global burden of TB disease is exacerbated by a number of factors including a 
decline in health care systems, overpopulation, accumulation of enclosed working and living 
areas, HIV/AIDs, economic constraints and drug resistance. TB is a particular source of 
frustration in Africa due to the high incidence of HIV/AIDs, which results in greater 
susceptibility to TB, thus leading to an increased prevalence of HIV-TB co-infection. 
Statistics show that about 75 % of the HIV positive people who developed TB in 2012 were 
in the African region (WHO, 2013). Furthermore, 3.5 % of new patients and 20.5 % of 
previously treated individuals developed multi-drug resistant TB (MDR), with 9 % of these 
being subsequently diagnosed as having extensively resistant TB (XDR) (WHO, 2013). 
The causative agent of TB, as identified in 1882 by Dr Robert Koch, is Mycobacterium 
tuberculosis (Mtb),  a rod shaped, acid-fast organism that contains a genome with a high G/C 
content (Sidders and Stoker, 2007). It is non-spore forming, has no evidence of a flagellum, 
with  cell width varying between 0.3 – 0.6 µm and length between 1 – 4 µm (Ducati et al., 
2006). Mtb is categorized as a slow growing intracellular pathogen which primarily infects 
macrophages and can lay dormant in an immuno-competent individual for decades (Sidders 
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and Stoker, 2007). The genome of Mtb H37Rv is approximately 4.4 x 10
6
 bp with ~4000 
open reading frames expected to encode genes required for various components of primary 
and secondary bacteria metabolism (Cole et al., 1998). 
1.2. TB Vaccines 
There is currently one TB vaccine in use, the Bacillus Calmette-Guérin (BCG) live-
attenuated vaccine, which was discovered over a century ago and is administered 
intradermally. However, there is a high degree of variability in protection between 
individuals. Even though effective protection has been shown for miliary TB and TB 
meningitis in children, pulmonary TB protection reduces as adolescence commences and 
significantly diminishes in adulthood (Fine, 1999). BCG vaccination does not protect 
individuals against latent infection and in its current format, it cannot be used in a prime-
boost manner and hence, cannot exert additive protection in adults (Dietrich et al., 2006). The 
lack of a protective or prophalyactive vaccine in adults has necessitated the search for new 
TB vaccines. 
Currently, there are three key approaches being utilized in the search and development of 
novel vaccines: (I) TB subunit vaccines which target specific antigens, (II) live-attenuated 
vaccines (mycobacterial) which express a broader range of antigens and (III) live Mtb which 
is substantially attenuated (Lin and Ottenhoff, 2008). At present, 12 vaccine candidates for 
Mtb are in different phases of clinical trials, most focusing on the prevention of TB either 
pre- or post- exposure (WHO, 2013). One of the candidate vaccines that recently underwent 
Phase IIb trials is MVA85A, a poxvirus which expresses the Mtb 85A antigen, it displayed 
satisfactory protective profile when tested in HIV negative children – i.e. it is immunogenic 
and tolerated – but demonstrated no major protection with regards to Mtb infection (Tameris 
et al., 2013). MVA85A is currently undergoing experimentation in HIV negative as well as 
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positive adolescents and adults with the hope that protection is observed in these cohorts. A 
novel, successful vaccine in combination with a successful drug regiment is one of the only 
hopes left to truly combat this disease. 
1.3. Antimicrobial Chemotherapy 
TB treatment involves the administration of chemotherapy for the duration of 6 months, for 
drug sensitive TB, using a combination of first line and second line drugs. The current 
recommended treatment regimens according to WHO guidelines consists of 2 months of 
combined Pyrazinamide (PZA); Isoniazid (INH); Ethambutol (EMB) and Rifampicin (RIF), 
followed by four months of INH and RIF (WHO, 2013, Ducati et al., 2006). However, there 
is a rapid increase in drug resistance, due to various reasons including non-compliance (as 
patients begin to feel better and do not complete treatment), poor drug availability in certain 
settings, cross-reactivity with other medications such as anti-retroviral therapy and 
prescription of inappropriate treatments. This has led to the emergence of MDR, XDR and 
totally drug resistant (XXDR/TDR) TB (Gandhi et al., 2006, Migliori et al., 2007, Velayati et 
al., 2009). MDR is defined as a resistance to RIF and INH (first line drugs), XDR comprises 
MDR, with the added resistance to at least two classes of the second line drugs, a 
fluoroquinolone and one more class, while XXDR is resistance to all standard drugs, first and 
second line (Anderson et al., 2012, Velayati et al., 2009). 
Drug resistance can occur due to a number of reasons including selective pressure under 
stressful conditions (changes in pH, low nutrients, etc.), genetic mutations, lateral gene 
transfer, as well as some microbes having an inherent resistance to specific classes of 
antibiotics (Depardieu et al., 2007). In mycobacteria, not much has been found regarding 
gene transfer, but the emergence of resistance to first line drugs has been primarily attributed 
to mutations in specific drug target genes. The main mutations were associated with genes 
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such as embB (EMB resistance); rpoB (RIF resistance); pncA (PZA resistance); katG and 
inhA (INH resistance) (Telenti et al., 1993, Zhang, 2005, Telenti, 1997, Ramaswamy et al., 
2003). There are 5 main classes of TB antimicrobial drugs which are administered either 
orally or are injected, with some of the second line drugs including Fluoroquinolones, 
Ethionamides, Aminoglycosides, D-cycloserines and Peptides (Zumla et al., 2013). Second 
line drugs are quite expensive, not as effective and very toxic with numerous adverse side 
effects experienced by patients. Consequently, treatment of MDR TB is complicated and 
requires extended treatment periods with various combinations of second line drugs.  
The abovementioned drugs are over five decades old and thus there is a dire need for new 
drug candidates that would form the basis on new regimens with an associated shortening of 
the treatment duration and reduction in daily pill burden. With regards to MDR treatment, 
which may take up to 20 months, new drugs are required to effectively manage this form of 
TB as well as decrease the side-effects associated with MDR management. There are a 
number of drugs at different testing phases in the pipeline. One of the most promising new 
drugs is in phase II and III trials, Rifapentine, which when used in combination with first line 
drugs, results in culture-negative smears in 8 weeks instead of the 16 weeks it takes with the 
current treatment (Dorman et al., 2012). Another drug which has gained much interest and is 
currently in phase II trials is Bedaquiline. This drug is of particular interest with regards to 
MDR treatment and has already been implemented, thus making it the first new drug to be 
added to the TB treatment regimen in over 50 years (WHO, 2013). Bedaquiline was added to 
the current MDR-TB treatment regimen in a double-blinded study which resulted in an 
increase in sputum culture conversion and a significant decrease in the time it took for 
sputum conversion to take place (Diacon et al., 2012b). This result was further confirmed by 
another study using a very similar treatment regimen, this time with the inclusion of XDR 
patients as well as HIV positive individuals on ARV treatment (Kakkar and Dahiya, 2014). 
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This drug has also been tested as a combination therapy with pyrazinamide, PA-824 and 
moxifloxacin, which revealed an accelerated activity of bedaquiline in the presence of 
pyrazinamide (Diacon et al., 2012a).  
1.4. TB Pathogenesis 
Pulmonary TB transitions through four stages; beginning with inhalation of tubercle bacteria 
within infectious aerosol particles, which were expectorated by a diseased individual. At this 
point, no environmental reservoir for Mtb has been found and transmission occurs direct from 
person-to-person (Ducati et al., 2006). After inhalation, bacteria are endocytosed by alveolar 
macrophages and those which escape destruction, proliferate by preventing fusion of the 
endosome with lysosomes (van Crevel et al., 2002, Dorhoi et al., 2011). The second stage 
commences with the recruitment of blood monocytes, and other lymphocytes, that have the 
ability to differentiate into macrophages. This subsequently causes a ‘symbiotic stage’ where 
macrophages amass and the bacteria grow exponentially within these cells. Thereafter, 
development of T cell immunity occurs where immune cells aid in mycobacterial antigen 
presentation, which eventually results in secretion of cytokines in order to eliminate the 
bacteria (van Crevel et al., 2002, O'Garra et al., 2013). Once exponential growth ceases, the 
third stage of disease commences where active disease develops through robust bacterial 
growth; cell mediated immunity and inflammation which leads to cavity formation (van 
Crevel et al., 2002, Chao and Rubin, 2010). Alternatively, a clinically latent state is 
established, with the outcome of disease being dependent on a number of factors, especially 
the immune status of the individual (Hett and Rubin, 2008, van Crevel et al., 2002, Chao and 
Rubin, 2010, O'Garra et al., 2013). 
Latent TB infection (LTBI) refers to those individuals who are infected with Mtb but do not 
display any symptoms of the disease. This form of TB is characterized by a PPD positive 
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result and affects more than 1/3 of the world’s population with approximately 10% of these 
cases developing active disease during the course of their lives (WHO, 2013). A major 
problem associated with latent TB is that it is asymptomatic and thus goes undetected in the 
majority of cases. LTBI has been described as an ‘equilibrium between host and bacillus’ and 
the term latency is more accurately ascribed to a diseased (or lack thereof) state rather than 
the growth status of tubercle bacteria (Flynn and Chan, 2001). In the past, latent infection has 
been associated, albeit with no substantive evidence, with dormancy, which primarily refers 
to a microbiological state usually found in the laboratory where bacteria enter a reversible 
state of metabolic inactivity or quiescence (Wayne and Sohaskey, 2001). Whilst it has been 
demonstrated that Mtb has the ability to enter a state of dormancy in vitro, as a survival 
mechanism, how this relates to latent infection remains a mystery (Deb et al., 2009, Shleeva 
et al., 2002). For the purposes of this study, we will use the above-mentioned definitions of 
dormancy and latent infection.  
Persistence is defined as, “continuing firmly or obstinately in an opinion or course of action 
in spite of difficulty or opposition,” according to the Oxford dictionary. This has been 
demonstrated to be an apt description for tubercle bacteria, which are able to survive in cells 
that are purposed to destroy such organisms and as such, have the ability to evade elimination 
by the host’s immune system as well as the prolonged antibiotic treatment (Gomez and 
McKinney, 2004). The ‘Cornell model’ has been used in mice to determine the antimicrobial 
effect/s in the lungs and spleen in the murine model of TB infection (McDermott, 1959). 
These studies revealed that initial treatment with drug results in rapid decline of the lung 
bacillary load to a level that is below detection. However, upon immune suppression, bacteria 
re-emerge in the lungs of these animals, suggestive of the presence of a bacteria that have 
persisted in the face of antibiotic treatment. These organisms are still drug-sensitive and are 
7 
 
referred to as persisters (McDermott, 1958). This state can be seen as distinct from the non-
replicating, spore forming state that some species adopt. 
Bacillus species adapt to unfavourable conditions through the formation of spores which 
involves global remodelling of metabolism and cell architecture (McKenney et al., 2013). It 
has been demonstrated that subsequent germination from sporulation is triggered by 
muropeptides, which are peptidoglycan (PG) breakdown products, probably released during 
PG remodelling, with muropeptides from a culture of replicating cells proving to be more 
effective inducers of germination when compared to PG from cells in the stationary phase 
(Dworkin and Shah, 2010). Although Ghosh and colleagues (2009) reported endospore 
formation in M. marinum and M. bovis BCG, the finding was disputed due to the lack of 
some genes, critical for spore formation, in the mycobacterial genome. The phenotypic 
similarity of the alleged mycobacterial spores to those observed in Bacillus spores, combined 
with the inability of four separate laboratories to reproduce the result, suggests that the initial 
report for spore formation is incorrect (Ghosh et al., 2009, Traag et al., 2010). However, 
mycobacteria do retain the capacity to enter into a viable but non culturable (VBNC) state of 
non-replicating metabolic quiescence (Shleeva et al., 2004, Wayne, 1994). Moreover, this 
state is reversible since tubercle bacteria can spontaneously reactivate in these in vitro models 
of dormancy suggesting that global modulation of metabolism does occur during these shifts 
in growth state (Chao and Rubin, 2010). However, whether mycobacteria adopt physical 
changes during the transition to dormancy remains to be investigated. Previous work has 
demonstrated the presence of ovoid cell forms in cultures of dormant M. smegmatis (Anuchin 
et al., 2009). The abovementioned observations in Bacillus provide evidence for a strong link 
between remodelling of the PG and bacterial dormancy/ reactivation, suggesting that an 
enhanced understanding of PG remodelling may provide deeper insight into the mechanism 
of reactivation in mycobacteria. Of particular importance in this regard are the proteins 
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annotated as resuscitation-promoting factors (Rpfs) which have been implicated in 
reactivation of Mtb from dormancy. These proteins are also postulated to play an important 
role in compositional and structural remodelling of the PG layer, thus affecting the growth 
state of the bacterium (Kana and Mizrahi, 2010). Rpfs are discussed in detail in section 1.7.1. 
1.5. Mycobacterial Cell Wall 
The cell envelope in mycobacteria is classified as gram variable since it differs from both 
gram positive and negative cell wall structures (Glickman and Jacobs, 2001). Structurally, 
mycobacteria are gram positive due to the presence of a substantial PG layer and no true 
outer membrane (OM). However they contain porins, a periplasmic-like space and do not 
retain the gram stain, which are properties shared by Gram negative organisms (Hett and 
Rubin, 2008).  
The cell wall of mycobacteria is unique in the sense that it is lipid rich, hydrophobic and 
extremely thick (Sidders and Stoker, 2007). The structure, as shown in Figure 1.1, comprises 
an outer layer (lipids and proteins), and an inner layer which consists of three main 
components: PG, arabinogalactan (AG) and mycolic acids (MA). These form a complex, 
comprising the PG layer, followed by a phosphodiester bridge connecting the PG to the AG, 
to which the MAs are anchored (Jarlier and Nikaido, 1994). This dense core has an impact on 
the growth of the bacterium, its success as a pathogen, the ability to survive and persist under 
stress, as well as the bacterium’s inherent resistance to antibiotics.  
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Figure 1.1. Diagram of the mycobacterial cell wall. The wall consists of a lipid bilayer (plasma membrane), 
followed by the PG to which arabinogalactan and lipoarabinomannan is attached by either a phosphate linker 
region or phosphatidylinositol anchor, respectively. MAs are esterified to the AG layer. Adapted from (Basso et 
al., 2005). 
 
MAs are long chain β-hydroxy acids which are substituted by α –alkyl groups, made up of 
alkelyl or cyclopropyl groups consisting of multiple carbons, generally 60-90 per chain 
(Anderson et al., 2012, Hett and Rubin, 2008). These lipid chains lie alongside each other at a 
90-degree angle to the cell surface. The MA comprises the outer layer of the cell wall and 
constitutes the major determinant of cell permeability in mycobacteria (Jarlier and Nikaido, 
1994, Sani et al., 2010). A few other mycolic acids of interest have been identified, these 
include the Cord factor and trehalose-6,6’-dimycolate (TDM), which is the lipid molecule 
responsible for the cord-like formations or clumping viewed when mycobacteria are grown in 
liquid culture and has been associated with pathogenicity (Lederer et al., 1975, Brennan and 
Nikaido, 1995, Takayama et al., 2005). Other such lipids gaining interest include phtiocerol 
dimycocerosate (DIM/pDIM), lipoarabinomannan (LAM) etc. (Brennan and Nikaido, 1995). 
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MAs are esterified to AG and thus AG plays a role of anchorage of the MAs to the PG (Hett 
and Rubin, 2008). This layer is generally referred to as the mycolyl-AG layer. AG is the 
major polysaccharide of the mycobacterial cell wall and adopts a branched-chain structure 
with  non-reducing termini formed by the arabinose (Ara) residues (Brennan, 2003). Both the 
arabinose (Araf) and galactose (Galf) are in the furanose confirmation with branching 
occurring at specific positions in this structure (Crick et al., 2001). MA attachment occurs in 
clusters of four, with two thirds of the total MAs  being attached to the terminal Ara motifs 
(Brennan and Nikaido, 1995). Attachment of this matrix to the PG occurs by linkage of 
muramic acid on PG (via a phosphodiester link) to position 6 of Galf via a ‘linker region’ 
(McNeil et al., 1990). There are 3 main forms of MAs,  α-; keto- and methoxy- MAs, which 
play different roles in pathogenicity and their ability to stimulate immune responses 
(Verschoor et al., 2012). In C. glutamicum, the presence of mycolic acid has been associated 
with the process of glutamate excretion (Gebhardt et al., 2007). In mycobacteria, mycolic 
acids are pivotal for growth and have been implicated in antimicrobial resistance (Marrakchi 
et al., 2014). 
1.5.1. Peptidoglycan (PG) layer 
The PG layer functions as a protective layer for the bacterial cell and plays an important role 
in determining cell shape and size. Due to this layer being unique to bacteria and the vast 
number of enzymes associated with it, it is an important target for antimicrobial drugs. The 
mycobacterial PG layer consists of repeating N-acetyl muramic acid (NAM) and N-acetyl 
glucosamine (NAG) residues held together by β-1,4-glycosidic linkages with peptide chains 
attached to the NA/GM residues of the glycan backbone. The peptide chains are made up of 
different residues, with L-alanine (L-Ala) at position 1, D-glutamine (D-iGln) at position 2, 
meso-diaminopimelic acid (m-DAP) at position 3, and D-alanine (D-Ala) at positions 4 and 5, 
Figure 1.2. and Figure 1.3. A unique feature in mycobacteria is the presence of N-
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glycolylated muramic acid (in addition to N-acetylated muramic acid), Figure 1.3 (Vollmer et 
al., 2008a). The N-glycolylation has been attributed to a hydrolase, encoded by the namH 
gene, with deletion of this gene causing only N-acetylation to take place (Raymond et al., 
2005). Specific enzymes act on the above-mentioned residues to yield cross-links between 
the peptide chains of the PG layer, thus connecting the glycan strands to create a three 
dimensional matrix (Park, 1995). Linkage of the peptide side-chains results in the formation 
of either a 43 cross-link or 33 cross-link between the side chains, Figure 1.3. 
Mycobacterial cell walls contain both 43 and 33 cross-links between the peptide chains 
which are generated by DD-transpeptidation or LD-transpeptidation, respectively (Lavollay et 
al., 2008). LD-transpeptidases are discussed in detail in section 1.7.2. 
It is hypothesized that mycobacterial PG synthesis occurs in a step-wise fashion with 
numerous reactions. The initial reaction involves synthesis of the uracil diphosphate (UDP) -
NAM from UDP-NAG, followed by synthesis of the UDP-NAM-pentapeptide side chain 
beginning with L-Ala and ending with D-Ala. At this point the subunit is transferred to the 
cell membrane where UDP of the NAM is released by attachment of bactoprenol phosphate 
(lipid I), thereafter lipid I is converted to lipid II and the resultant PG subunit (lipid II) is 
flipped across the membrane, Figure 1.2. (Crick et al., 2001). It is at this stage that PG 
assembly, cross-linking, remodeling etc. can take place in the periplasmic compartment 
(Sobhanifar et al., 2013, Gee et al., 2012). The constant growth and cell division processes 
demand that PG remains a dynamic structure which is constantly remodelled to allow for a 
variety of functions including shape maintenance, replication and division of cells. This 
process of PG turnover is facilitated by PG hydrolases.  
12 
 
Figure 1.2. Diagram of PG synthesis. Biosynthesis of a PG subunit occurs in the cytoplasm and it is thereafter 
flipped into the periplasm where incorporation of the subunit into the PG chain occurs. Adapted from (Pinho et 
al., 2013, Vollmer et al., 2008b). 
 
Figure 1.3. PG structure and sites of action of a few hydrolases acting on the bonds of PG. Cross-links are 
formed either by Ldts (LD-transpeptidases) or high molecular weight PBPs. DD-CPases (DD-Carboxypeptidases) 
cleave the terminal D-Ala, freeing the terminal residue. Adapted from (Vollmer et al., 2008b, Kana and Mizrahi, 
2010). 
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1.6. Mycobacterial Growth 
The constant remodeling of PG, i.e. the breakdown and synthesis, is a key process for 
successful bacterial growth and cell division. In rod-shaped bacteria such as E. coli and B. 
subtilis, which are the best studied, new PG is inserted along the cells axis with a left- or 
right- handed helical pattern, respectively, Figure 1.4 (Wang et al., 2012, Mendelson, 1976). 
These organisms have two modes of growth which occur separately; i.e. cell division 
controlled by the divisome and cell elongation controlled by the elongasome, with each mode 
containing a specific set of proteins present in complexes to efficiently carry out these 
processes (Cabeen and Jacobs-Wagner, 2005, Jacobs and Shapiro, 1999). 
Elongation of E. coli is determined by an actin-like protein MreB which plays an important 
role in localization of new PG synthesis and has a role in maintaining the rod-shape of these 
organisms (Wang et al., 2012). MreB also functions in a complex with other Mre proteins as 
well as RodA, which aids and allows FtsZ-ring co-ordination to take place (Young, 2010). 
FtsZ is a tubulin-like protein. B. subtilis has MreB as well as Mbl, with MreB implicated in 
the control of the width of the cell and Mbl involved in the control of the length of the linear 
axis of the cell (Jones et al., 2001). Due to the manner in which these organisms grow, inert 
PG is found at the poles, which is not the case in mycobacteria (Hett and Rubin, 2008). 
The divisome of both E. coli and B. subtilis is initiated by FtsZ, which works in concert with 
approximately eleven other proteins in a complex in order to form the Z-ring at the mid-cell 
position for initiation of cell division (Bi and Lutkenhaus, 1991, Adams and Errington, 2009). 
The precise placement of the Z-ring in these organisms is dependent on ‘negative control 
systems’, namely the Min system (made up of MinCDE/ MinCD DivIVA) and the nucleoid 
occlusion system (Noc/SlmA) which function by either preventing the formation of the Z ring 
or prevents FtsZ polymerization, respectively (Hu and Lutkenhaus, 2000). These functions 
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are triggered by the length of the cell, thus producing a division event which results in 
symmetrical cells, each of which contains a nucleoid, Figure 1.4 (Trueba, 1982).  
Figure 1.4. Diagram of cell division of different rod-shaped organisms. E. coli incorporates new PG in a left-
handed helix along the cell wall, while B. subtilis incorporates PG in a right-handed helix along the cell wall to 
produce cells of the same length. Mycobacteria incorporate new PG at the poles and separate by ‘snapping’ 
which produce cells of different lengths. Adapted from (Adams and Errington, 2009, Santi et al., 2013). 
 
Mycobacterial cell division differs greatly from other rod-shaped bacteria. The main 
difference being that mycobacteria grow from the poles instead of along the axis, which 
results in two cells in a V-shaped confirmation that divide by a mechanism referred to as 
‘snapping’ (Thanky et al., 2007). Mycobacteria seem to be missing many of the proteins 
described for the division of E. coli and B. subtilis. While a homologue of FtsZ is present, the 
difference is that the MreB proteins described are absent and although there may be other 
actin-like proteins which could serve the function of the MreB family, none have been 
described in mycobacteria yet. Hett and Rubin (2008) hypothesized that due to these features, 
FtsZ is the determining factor of both elongation and septation. Other cell division proteins 
that are not found in mycobacteria include FtsA and potentially ZipA, which act to stabilize 
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the Z-ring. Another interesting feature of the FtsZ of mycobacteria is its inherently slow 
polymerization, the role for which has not been fully elucidated yet (Hett and Rubin, 2008). 
FtsZ in mycobacteria seems to function in a similar fashion as in other rod-shaped bacteria 
with the presence of multi-protein complexes. One such complex is demonstrated by FtsZ-
FtsW-PBP3 (FtsI), where the FtsZ and FtsW directly interact and thus FtsW acts as a 
connecting molecule, together suggesting that cell division and synthesis of septal PG is 
dependent on the interaction of a multitude of proteins which form complexes (Datta et al., 
2006, Rajagopalan et al., 2005). DivIVA plays a role as a polar determinant in other 
organisms, and its homologue in mycobacteria, Wag31, acts as a guide for growth at the 
poles (Cava et al., 2013, Meniche et al., 2014). This protein interacts with FtsI (PBP3), and 
acts to protect FtsI from oxidative stress re-iterating the importance of protein complexes in 
cell division (Mukherjee et al., 2009). 
Mycobacteria  lack the Z-ring negative regulator systems, i.e. the Min system and nucleoid 
occlusion and is possibly the  reason that the mycobacterial Z-ring does not always form at 
the mid-cell (Singh et al., 2010). In E. coli and B. subtilis, these systems are dependent on 
cell length in order to produce symmetrical cells (Trueba, 1982). Studies have shown that 
mycobacteria produce mostly symmetrically dividing cells of different lengths (Joyce et al., 
2012, Vijay et al., 2014). Singh and colleagues (2013) stated that to compensate for the 
absence of these regulators, DNA translocation is directional and polar growth occurs 
unevenly following FtsZ ring assembly. They also showed that the daughter cells all 
produced viable cells, even though growth and division occurred at varying rates, with the 
presence of both bi- and uni- polar growth (Singh et al., 2013). A recent study has shown that 
Mtb also has a small percentage of cells with asymmetric mid-cell placement (defined as > 10 
% septum position deviation) producing a short and long cell – in this case due to septum 
placement, and not growth of the poles (Vijay et al., 2014). All resultant cells, including the 
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short cells, as well as division events contained intact nucleoids with the short cells being 
neither VBNC cells nor spores, as they divide normally (Vijay et al., 2014). M. smegmatis 
cells have been shown to produce a higher degree of asymmetric cells when compared to E. 
coli and B. subtilis with growth occurring preferentially at one pole (Aldridge et al., 2012). 
This gives rise to ‘accelerator’ and ‘alternator’ cells, depending on which daughter inherits 
the growing pole and cell division in mycobacteria is controlled/triggered by time instead of 
size of the cells (Aldridge et al., 2012). Another study focusing on division events of XDR 
and XXDR Mtb strains demonstrated that asymmetric division occurrence increased in XDR 
and XXDR strains compared to susceptible and MDR strains (Farnia et al., 2010). This study 
also revealed that the highly resistant strain produces ‘round bacilli’ and branching, with the 
round cells hypothesized to disseminate faster and could be a driving force in the virulence of 
these strains (Farnia et al., 2010).  
As demonstrated, cell division is dependent on a number of enzymes working collectively, 
many of which are hydrolases, which function to breakdown certain components in the cell 
wall.  
1.7. PG Hydrolases 
The PG hydrolases in bacteria act by hydrolyzing different bonds in the PG matrix which 
facilitate a number of processes including cell growth and division, shape maintenance, PG 
remodeling for insertion of secretion apparatus etc. In gram negative bacteria they also play a 
role in PG recycling, while in the gram positive Bacillus sp. they have been shown to play a 
role in spore germination and release of muropeptides, which could act as signaling 
molecules for resuscitation of dormant cells (Shah et al., 2008, Dworkin and Shah, 2010, 
Nikitushkin et al., 2013).  
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The cell requires a variety of PG hydrolases with diverse modes of action in order to carry 
out the array of activities described. There are generally a number of hydrolases with similar 
function (referred to as functional redundancy), with these functions being essential in 
maintaining the integrity of the cell. There is a hydrolase which could act on every bond 
present in PG (Sobhanifar et al., 2013). PG hydrolases act on the three types of bonds present 
in the PG sacculus – glycosidic (glycosidases), amide (amidases) and peptide (peptidases) 
bonds. Glycosidases are involved in glycan backbone cleavage, and consist of N-
acetylglucosamidases and N-acetylmuramidases which are sub-divided, based on cleavage 
products, into lysozymes and lytic transglycosylases (LTs) (Frirdich and Gaynor, 2013). LT-
cleavage of PG results in the terminal NAM residue containing a 1,6-anhydro ring while 
products of lysozyme cleavage lack this ring. 
Amidases (N-acetylmuramyl-L-alanine amidases) on the other hand, remove the entire 
peptide side chain by cleavage between NAM and L-Ala (Schomburg and Salzmann, 1991). 
In a bioinformatics analysis by Machowski et al. (2014), four amidase homologues were 
identified in Mtb and annotated as ami1, ami2, ami3 and ami4, with the former two 
containing an amidase_3 domain, while the latter two contain an amidase_2 domain. 
Amidases play a role in cell communication, cell separation and antibiotic resistance in other 
organisms, as well as sporulation and germination in Bacillus sp. (Heidrich et al., 2001, 
Smith et al., 2000). A recent study demonstrated that based on the structural and biochemical 
properties of Mtb ami1 (Rv3717), as well as the ability of Rv3717 to act on PG fragments 
and accept transposon insertions, this enzyme could play a role in the recycling of PG, which 
has not been described in Mtb as yet (Prigozhin et al., 2013, Griffin et al., 2011). A second 
distinct study has shown Ami2 to be essential in the environmental strain M. smegmatis and 
further demonstrate that Ami1 plays a pivotal role in cell division (Senzani and Kana, 
Unpublished). 
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Peptidases, which cleave within the peptide side chain, are generally penicillin binding 
proteins (PBPs) and include endopeptidases and carboxypeptidases. One of the best 
characterized endopeptidases in Mtb is RipA (Rpf-interacting protein A) which, together with 
RipB, contains a NlpC/p60-like domain (Both et al., 2011). RipA (Rv1477) and RipB 
(Rv1478) were shown to hydrolyze the bond between D-Glu (position 2) and mDAP (position 
3) and thus have a role in cell-wall remodeling (Both et al., 2011). However, they have 
differences in both substrate specificity and N-terminal fragments. RipA, an essential gene in 
Mtb, is a zymogen (requires proteolytic cleavage to activate the protein) whose expression 
must be tightly regulated as studies in M. smegmatis have shown that depletion causes 
chaining of cells and over-expression causes lysis (Chao et al., 2013). RipA is hypothesized 
to play a role in exit from dormancy as it interacts with and forms a complex with RpfB or 
RpfE and this hydrolysis is controlled/modulated by a high molecular weight (HMW) PBP, 
PBP1, by competition between RpfB/E and PBP1 for RipA (Hett et al., 2007, Hett et al., 
2010, Patru and Pavelka, 2010, Hett et al., 2008). A bioinformatics analysis of the genome of 
Mtb revealed 3 other endopeptidase homologues – Rv0024, RipD and Rv2190 (Machowski 
et al., 2014). 
1.7.1. Resuscitation Promoting factors (Rpfs) 
Rpf, a secreted protein, was first described in Micrococcus luteus as an essential gene which 
plays a role in resuscitation of dormant forms of the bacterium (Mukamolova et al., 1998). In 
2006, Mukamolova et al showed this enzyme to be muralytic. Consistent with this, Rpfs bear 
strong structural similarity to lysozymes and are hence hypothesized to cleave between the 
NAM and NAG residues (β 1-4 glycosidic bond) of PG and accordingly are classified as lytic 
transglycosylases (Cohen-Gonsaud et al., 2005, Ruggiero et al., 2009, Mukamolova et al., 
2006). Mycobacteria retain multiple rpf homologues with M. smegmatis containing four 
(rpfA, rpfB and a duplication of rpfE – based on gene synteny), whereas Mtb contains five: 
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rpfA-rpfE which are collectively dispensable for growth but are required for virulence in the 
murine model of TB infection (Kana et al., 2008, Machowski et al., 2014). Furthermore, 
while these genes are dispensable under normal in vitro conditions, they become important 
for growth in the presence of cell wall stress. 
There is evidence to indicate a level of functional specialization within the rpf gene family in 
Mtb (Gupta and Srivastava, 2012). This has been demonstrated by deletion studies, where 
rpfB deletion alone and rpfB in combination with rpfA deletion caused colony forming 
defects as well as delayed reactivation of growth in mice (Tufariello et al., 2006, Russell-
Goldman et al., 2008). Triple rpf deletion mutants defective for different combinations 
resulted in resuscitation impairment and varying attenuation effects in mice (Downing et al., 
2005). With regards to a functional hierarchy, Kana et al (2008) demonstrated that rpfB and 
rpfE rank highest in terms of their ability to restore a plating defect in the quintuple rpf 
deletion mutant, which is particularly significant as both enzymes have been shown to 
interact with RipA for enhanced PG hydrolysis (Hett et al., 2008). This interaction is 
hypothesized to play a role as the driving force of resuscitation in Mtb as dormant cells have 
been shown to contain a thicker cell wall (Mukamolova et al., 1999).  
A study by Mukamolova and colleagues (2010) confirmed that sputum from patients with 
smear positive TB contains an Rpf dependent population of Mtb, leading to the hypothesis 
that Rpfs may play a role in the transmission of TB disease (Mukamolova et al., 2010). The 
mechanism of reactivation by Rpfs is still largely unknown, however a recent study has 
shown that high molecular weight PG fragments have the ability to induce resuscitation in 
specific media (Nikitushkin et al., 2013). This led to the theory that Rpfs could produce 
signalling molecules in the form of muropeptides in order to trigger resuscitation, which is an 
attractive idea since Mtb contains PrkC and PknB homologues as well as the PASTA-binding 
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domain, all involved in muropeptide recognition in other organisms such as Bacillus sp. 
(Foulquier et al., 2014, Squeglia et al., 2013) 
As cells approach stationary phase, the growth of BCG was enhanced through 
supplementation with Rpfs, whereas these same proteins had no effect on exponentially 
growing cells (Mukamolova et al., 2002). This is consistent with the role of Rpfs in 
resuscitation. Entry into stationary phase also increases 33 cross-links in mycobacterial sp., 
which could also be the case in dormant bacteria, resulting in a cell wall that is more resistant 
to hydrolases (Lavollay et al., 2008). 
1.7.2. L,D-Transpeptidases (Ldts) 
Ldts are responsible for the formation of the 33 cross-links between stem peptides by 
cleavage between D-Ala at position 4 and mDAP at position 3 of the peptide stem and 
subsequent linkage between mDAP residues (Mainardi et al., 2005). 33 cross-links have 
been implicated in adaptation to stationary phase in mycobacteria and thus to cells with a 
decreased metabolic rate as mentioned in the previous sections (Lavollay et al., 2008). These 
observations point to a role for Ldts in adapting to growth phase-specific needs. However, a 
recent study reported evidence that 33 cross-links predominate at all stages of growth and 
hypothesized that transpeptidases identify amidation of the desired residues and control 
cross-linking in this way, with Ldts containing a preference for the substrate of an ε-carboxyl 
donor stem which is unamidated (Kumar et al., 2012). Hence, a definitive conclusion requires 
further analysis, but most studies support the former hypothesis, as this is consistent with 
experiments conducted in other organisms.  
Mtb contains five putative Ldts annotated LdtMt1-LdtMt5, with LdtMt1 and LdtMt2 being the best 
studied (Gupta et al., 2010). Kumar and colleagues (2012) demonstrated that Ldts, as well as 
DD-CPases, are sensitive to carbepenems. Carbepenems act on the cell wall by inhibiting 
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synthesis and have the added advantage of containing an inherent resistance to β-lactamases 
(Papp-Wallace et al., 2011). Loss of LdtMt2 only and both LdtMt1 and LdtMt2 resulted in a 
number of defects including morphological alterations; reduced growth in liquid culture; 
decreased virulence; altered localization of a number of proteins (including a number of low 
molecular weight proteins); increased vulnerability to vancomycin, as well as a combination 
of amoxicillin-clavulanate (Gupta et al., 2010, Schoonmaker et al., 2014). These defects were 
much more pronounced in the double mutant, pointing to a potential functional redundancy 
between the ldt genes. The above-mentioned results suggest that Ldts, and possibly other low 
molecular weight PBPs are associated. 
1.7.3. Penicillin Binding Proteins (PBPs) 
PBPs are implicated in PG synthesis/assembly and are thus named due to their ability to bind 
β-lactam antibiotics (Spratt, 1983). PBPs are acyl-serinetransferases whose molecular 
weights vary between 25000-100000 Daltons (Ghuysen, 1991). There are 3 main classes of 
PBPs – Class A and Class B, which consist of high molecular weight PBPs, and Class C, 
which consist of low molecular weight PBPs. Class A high molecular weight PBPs are bi-
functional enzymes which contain both transpeptidase (PB domain) and transglycosylase (n-
PB domain) activity, whereas Class B high molecular weight PBPs contain only 
transpeptidase activity (Spratt, 1983). With regards to class B PBPs, mycobacteria encode 
three – PbpA, PbpB (FtsI) and PBP-lipo, with the former two being implicated in M. 
smegmatis cell division (Machowski et al., 2014, Dasgupta et al., 2006). In other organisms 
such as E. coli, FtsI forms part of the divisome assembly complex in concert with other cell 
assembly proteins (Muller et al., 2007). 
Two class A PBPs have been identified in mycobacteria, ponA1 (PBP1) and ponA2 (PBP1A). 
A PBP1 mutant in M. smegmatis displayed an increased susceptibility to β-lactam antibiotics; 
increased permeability; as well as slower growth in liquid media (Billman-Jacobe et al., 
22 
 
1999). PonA2, which contains a PASTA domain, has been implicated in anaerobic and 
stationary phase adaptation with mutational studies resulting in increased susceptibility to 
antibiotics, as well as a number of discrepancies at the onset of stationary phase including the 
formation of spherical cells, cell surface changes, and survival and recovery defects (Patru 
and Pavelka, 2010). M. smegmatis contains a duplication of PonA2, which has been 
annotated as PonA3.  PBP1 has also been shown to interact with the endopeptidase RipA as 
described in section 1.7 (Hett et al., 2010). PBP1 homologues in E. coli and B. subtilis have 
been shown to be involved in cell division and elongation and play similar roles in 
mycobacteria (Basu et al., 1996, Claessen et al., 2008, Banzhaf et al., 2012). 
Class C low molecular weight PBPs consist of endopeptidase and carboxypeptidases. 
Endopeptidases have been discussed at the beginning of section 1.7, while the main focus of 
the current MSc is the carboxypeptidases. 
1.7.3.1. DD-Carboxypeptidases  
DD-CPases, class C low molecular weight PBPs, act to modify PG by cleavage of the 
terminal D-Ala residue of the pentapeptide side chain, Figure 1.3. These enzymes have a role 
in controlling cross-linking of PG (Ghuysen, 1991). Most organisms encode a number of DD-
CPases which are said to be enzymatically redundant with most being annotated as non-
essential genes. Studies have shown that while these enzymes control cross-linking, they are 
not directly involved in synthesizing them (Hammes and Seidel, 1978). 
DD-CPase activity has not been characterized in most organisms, with best studied DD-CPase 
genes being those of E. coli and, to a lesser extent, B. subtilis. E. coli encodes four DD-
CPases – PBP4, PBP5, PBP6 and DacD, with PBP4 containing bifunctional activity i.e. 
endopeptidase and carboxypeptidase activity, its primary activity being as an endopeptidase 
(Ghosh et al., 2008). PBP5, encoded by dacA, is the most studied DD-CPase. Mutation of 
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PBP5 resulted in severe growth and morphological defects, while over-expression resulted in 
the formation of spherical cells (Ghosh and Young, 2003, Markiewicz et al., 1982). None of 
the other LMW PBPs can compensate fully for loss of PBP5, whereas in mutants lacking 
other DD-CPases, genetic complementation with PBP5 alone is able to reverse cell defects 
(Nelson and Young, 2001). The activity of this gene has been attributed to the presence of a 
Ω-loop in its Domain I region (Nelson et al., 2002). PBP6 shares a significant sequence 
homology to PBP5 and both are controlled by BolA (a transcriptional regulator), however 
their biological roles seem to differ as PBP6 has been implicated to have a function in the 
stationary phase (van der Linden et al., 1992, Ghosh et al., 2008, Chowdhury et al., 2012). 
DacD has the ability to partially compensate for loss of resistance to β-lactams in a PBP5 
mutant and its expression increases during mid-log phase of growth (Santos et al., 2002). It 
has been hypothesized that the differing DD-CPases function at different growth phases which 
points to these genes playing specific roles, dependent on which growth phase they are most 
active (Ghosh et al., 2008). 
B. subtilis encodes a number of DD-CPases including PBP4a (pbp), PBP5, PBP5* and DacF. 
PBP5* (dacB) is the most well characterized DD-CPase in this organism. It is synthesized 
only at later stages of sporulation, specifically stage III, and its role is hypothesized to be in 
the synthesis of the spore cortex (Todd and Ellar, 1983, Buchanan and Ling, 1992). The dacA 
gene encodes PBP5 – the vegetative DD-CPase which is expressed at the exponential phase of 
growth and is suggested to play a role in promoting the maturation of PG (Atrih et al., 1999). 
PBP4a (dacC), a DD-CPase with thiolesterase activity, is active during late stationary phase 
and retains sequence homology to E. coli PBP4 (Pedersen et al., 1998, Duez et al., 2001). Not 
much is known regarding DacF. It is expressed within the bacillus fore-spore during the 
stationary phase of growth and has been hypothesized to play a role during sporulation by 
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modifying PG (Popham et al., 1999). These findings are consistent with the premise that the 
action of different DD-CPases is indeed growth phase dependent. 
There have not been many studies focusing on DD-CPases from other organisms. There are a 
number of homologues which have been identified in different organisms, and this section 
will just highlight a few of the better characterized homologues. PBP3 of Neiserria 
gonorrhea contains homology to PBP4 of E. coli and has a role in PG biogenesis (Ghosh et 
al., 2008). PBP6b (DacD) of Salmonella enterica has sequence homology to E. coli DacD 
and both are hypothesized to play similar roles in the cell since DacD mutants in both 
organisms result in biofilm defects (Brambilla et al., 2014). PBP3 (dacA) of S. pneumonia 
seems to function in a similar fashion as E. coli PBP5, since mutants have severe 
morphological defects as well as a cell division defect (Severin et al., 1992, Morlot et al., 
2004). In P. aeruginosa, PBP5 also shows homology to E. coli PBP5 with the inclusion of 
carbapenemase (confers reisistance to the carbapenem class of antibiotics) action (Smith et 
al., 2013). Recently, the dacB gene of V. parahaemolyticus has been implicated in the 
initiation of VBNC cells through the production of irregularly shaped cells (Hung et al., 
2013). The presence of DD-CPases with conserved sequence homologies in a variety of 
microorganisms indicates the importance of these genes in the cell and the pivotal role they 
play in cell wall homeostasis. 
A recent analysis of the mycobacterial genome has revealed that Mtb has three DD-CPase 
homologues, namely Rv3627c; dacB1 and dacB2 (Machowski et al., 2014). The 
environmental mycobacterial sp., M. smegmatis, contains five putative homologues, dacB 
(Rv3627c homologue); MSMEG_2432; MSMEG_2433 (duplication of dacB2); 
MSMEG_1661 and MSMEG_1900 (Ealand and Kana, unpublished). Recent studies have 
focused on DacB2 of Mtb which, when over-expressed, caused a number of defects including 
biofilm and sliding motility defects, as well as alterations in colony morphology and a 
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reduction of growth (Bourai et al., 2012). Mutational studies resulted in a reduction of growth 
in minimal media under stressful conditions. The mutant strain also showed increased 
endurance in macrophages, which could indicate a function in pathogenesis (Bourai et al., 
2012). Kumar and colleagues (2012) demonstrated the ability of carbapenems (meropenem in 
particular) to inhibit DacB2, as well as one Ldt, and in turn cause pentapeptide accumulation, 
pointing to the possibility of these genes/proteins as targets for new drugs. 
This study focused on further elucidation of DD-CPases in M. smegmatis, a close homologue 
of Mtb routinely used as a model organism for TB research. As previously stated, 
bioinformatics analysis was conducted by Ealand and colleagues, who also tested expression 
levels of these genes, showing increased expression during logarithmic growth, with the 
MSMEG_2433 gene being the most highly expressed. Attempts were made to delete the DD-
CPase -encoding genes from the M. smegmatis genome, which confirmed the essentiality of 
dacB in M. smegmatis. These results form the backbone of this study since the essentiality of 
dacB combined with the increased expression of MSMEG_2433 during log-phase of growth 
prompted the selection of these two genes for further characterization in this study. The aims 
are outlined below. 
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1.8. Study Aims and Objectives 
Aim 
The aim of this study was to identify interacting partners for two putative DD-CPase-
encoding genes in M. smegmatis, dacB and MSMEG_2433, and to determine the localization 
of these proteins. Interacting partners were identified using a yeast-two hybrid system, the 
results of which could point to the presence of a protein complex that could have a pivotal 
role in the cell. Antibiotic susceptibility of single DD-CPase deletion mutants was also carried 
out to determine any changes in drug susceptibility profiles with regards to these genes.  
 
Objectives 
1. To construct two vectors carrying either the dacB or MSMEG_2433 genes as fusions 
to the Gal4 DNA binding domain (bait) 
2. To construct a library of the genome of M. smegmatis in a vector to create a library of 
fusion proteins to the Gal4 Activation Domain which will then serve as the prey for 
the screen. 
3. To identify the protein/s interacting with the M. smegmatis dacB and MSMEG_2433 
using the yeast two-hybrid system. 
4. To determine the localization of the DD-CPases in the cell by constructing in-frame 
fusions to a fluorescent protein. 
5. To determine the antibiotic susceptibility profiles of single gene DD-CPase knockouts 
(MSMEG_2432, MSMEG_2433 and MSMEG_1600). 
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2. Methods and Materials 
2.1. Bacterial Strains, Plasmids and growth conditions 
All bacterial strains and plasmids constructed and/or used in this study are listed in Tables 2.1 
and 2.2. Glycerol stocks of all strains were prepared using 33 % glycerol and stored at -70°C. 
N.B. All centrifugation steps were carried out at room temperature unless otherwise stated. 
 
Table 2.1. Bacterial strains used and/or created in this study 
Strain Genotype Reference 
E. coli 
Escherichia coli 
DH5α 
SupE44 ΔlacU169 hsdR17 recA1 
endA1 gyrA96 thi-1 relA1  
Promega, Madison, WI  
Escherichia coli Dam- ara-14 leuB6 fhuA31 lacY1 tsx78 
glnV44 galK2 galT22 mcrA dcm-6 
hisG4 rfbD1 R(zgb210::Tn10) Tet
S
 
endA1 rspL136 (Str
R
) dam13::Tn9 
(Cam
R
) xylA-5 mtl-1 thi-1 mcrB1 
hsdR2 
New England Biolabs, 
Ipswich, MA 
M. smegmatis 
mc
2
155 High frequency transformation mutant 
of M. smegmatis ATCC 607  
(Snapper et al., 1990) 
SRS Derivative of mc
2
155 carrying pMC1s, 
which encodes the tetracycline 
repressor, integrated at the attB 
bacterial phage attachment site, Kan
R 
 
C. Ealand (CBTBR) 
∆1661 Derivative of mc2155 carrying an 
unmarked MSMEG_1661 deletion of 
1158 bp 
C. Ealand (CBTBR) 
∆2433 Derivative of mc2155 carrying an 
unmarked MSMEG_2433 deletion of 
855 bp 
C. Ealand (CBTBR) 
∆2432 Derivative of mc2155 carrying an 
unmarked MSMEG_2432 deletion of 
792 bp 
 
C. Ealand (CBTBR) 
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Yeast 
AH109 MATa, trp1-901, leu2-3, 112, ura3-52, 
his3-200; gal4Δ, gal80Δ, LYS2 : : 
GAL1UAS-GAL1TATA-HIS3, GAL2UAS-
GAL2TATA-ADE2, URA3 : : MEL1UAS-
MEL1 TATA-lacZ 
 
(James et al., 1996) 
Clontech Laboratories Inc. 
Y187 MATα, ura3-52, his3-200, ade2-101, 
trp1-901, leu2-3, 112, gal4Δ, met–, 
gal80Δ,URA3::GAL1UAS-
GAL1TATA-lacZ 
(Harper et al., 1993) 
Clontech Laboratories Inc. 
 
Table 2.2. Plasmids used and/or created in this study 
Plasmids Genotype Reference 
pGADT7 Y2H vector to produce AD 
fusions, GAL4 (768-881) AD, 
LEU2, HA epitope tag; Amp
R
 
Clontech Laboratories Inc. 
pGBKT7 Y2H vector to produce BD 
fusions, GAL4(1-147) DNA-BD, 
TRP1, c-MYC epitope tag; Kan
R
 
Clontech Laboratories Inc. 
pSE100 E. coli-Mycobacterium shuttle 
vector carrying Pmyc1
tetO
; Hyg
R
  
(Ehrt et al., 2005) 
pTweety (pTTP1BG) Integration vector carrying an 
integrase gene; Genta
R
 
(Pham et al., 2007); Nicole 
C. Narrandes (CBTBR) 
pMC1s Shuttle vector carrying PSMYC–
tetR, integrates at the attB site on 
the mycobacterial genome; Kan
R 
 
(Ehrt et al., 2005) 
mCherry (pSB1C3) E. coli vector carrying mRFP, Kan
R (Shaner et al., 2004) 
Venus (pMK) E. coli vector carrying Venus, Kan
R (Petreanu et al., 2007) 
rsEGFP E. coli vector carrying rseGFP, 
KanR 
(Grotjohann et al., 2011) 
pGBKdacB Derivative of pGBKT7, carrying 
the 1443 bp dacB gene cloned as 
an in-frame fusion to the gal4 
promoter DNA binding domain 
Kan
R
 
This study 
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pGBK2433 Derivative of pGBKT7, carrying 
the 891 bp MSMEG_2433 gene 
cloned as an in-frame fusion to the 
gal4 promoter DNA binding 
domain Kan
R
 
This study 
pSEdacB-mCherry Derivative of pSE100, carrying the 
dacB gene with an in-frame C-
terminal fusion to the mCherry 
fluorescent gene Hyg
R 
This study 
pSEdacB-Venus Derivative of pSE100, carrying the 
dacB gene with an in-frame C-
terminal fusion to the Venus 
fluorescent gene Hyg
R 
This study 
pSEdacB-rsEGFP Derivative of pSE100, carrying the 
dacB gene with an in-frame C-
terminal fusion to the rseGFP 
fluorescent gene Hyg
R
 
This study 
pSE2433-Venus Derivative of pSE100, carrying the 
MSMEG_2433 gene with an in-
frame C-terminal fusion to the 
Venus fluorescent gene Hyg
R
 
This study 
pSE2433-rsEGFP Derivative of pSE100, carrying the 
MSMEG_2433 gene with an in-
frame C-terminal fusion to the 
rseGFP fluorescent gene Hyg
R
 
This study 
pTw::dacB-rsEGFP Derivative of pTweety carrying 
the tetO, dacB gene and rseGFP 
fluorescent gene Genta
R
 
This study 
Kan
R
 (Kanamycin resistant); Amp
R
 (Ampicillin resistant); Genta
R
 (Gentamycin resistant); 
Hyg
R
 (Hygromycin resistant)  
2.1.1. Growth of Mycobacterial Strains 
M. smegmatis was grown in Middlebrook 7H9 supplemented with 0.5 % glycerol, 0.085 % 
NaCl, 0.2 % glucose and 0.05 % tween 80 (referred to herein at 7H9), as well as the 
appropriate antibiotic, at 37 ºC overnight at a shaking speed of 100 rpm. For growth on solid 
media, Middlebrook 7H10 supplemented with 0.2 % glycerol, 0.085 % NaCl, 0.5 % glucose 
(referred to herein as 7H10) and the appropriate antibiotic was used with incubation at 37 ºC 
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for 3-4 days. Antibiotic concentrations used were as follows: 50 µg/mL hygromycin (Hyg), 
25 µg/mL Kanamycin (Kan) and 10 µg/mL Gentamycin (Genta). 
2.1.2. Growth of E. coli strains 
E. coli was grown in Luria-Bertani broth (LB) supplemented with the appropriate antibiotic at 
37 ºC overnight (unless otherwise stated). Luria-Bertani agar (LA) was used for growth on 
solid media. Antibiotic concentrations used were as follows: 200 µg/mL Hyg, 50 µg/mL Kan 
and 25 µg/mL Genta. 
2.2. DNA manipulation 
2.2.1. Mycobacterial DNA extraction  
2.2.1.1. Cetyltrimethylammonium bromide (CTAB) method 
Mycobacterial cells were initially heat killed at 65 ºC for 35 min followed by harvesting 
using centrifugation (3500 × g) for 10 min and the pellet was resuspended in 100 µL TE. 
Thereafter, 50 µL lysozyme (10 mg/mL) was added to each tube and incubated at 37 ºC for 1 
hour. A combination of 70 µL 10 % SDS and 6 µL proteinase k (10 mg/mL) was added to the 
tubes and incubated at 65 ºC for 2 hours. Following this, 100 µL 5M NaCl was added, mixed, 
and 80 µL pre-warmed NaCl/CTAB was then added to the mixture and vortexed. This was 
incubated at 65 ºC for 10 min. Approximately 800 µL chloroform:isoamyl alcohol (24:1) was 
added to each tube, mixed and centrifuged for 5 min. Aqueous layer was transferred to a 
clean tube, 0.6 volumes of isopropanol was added to this, tubes were inverted, placed on ice 
for 20 min and then centrifuged (16500 × g) for 20 min. The resulting DNA pellet was then 
washed twice with cold 70 % ethanol and pellet was dried in the speed vac for approximately 
15 min. Each pellet was resuspended in 40-60 µL TE buffer, quantified using the Nanodrop 
(Inqaba Biotech, South Africa) and stored at 4 ºC. 
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2.2.1.2. Colony boil for small-scale mycobacterial DNA extractions  
Half of the desired colony was picked and resuspended in 100 µL sterile water (sdH2O). 
Thereafter, 50 µL chloroform was added and the tube inverted 6 times. This was boiled at 65 
ºC for 15 min and centrifuged (16500 × g) for 2 min. The supernatant was transferred to a 
clean eppendorf tube and used immediately. 
2.2.2. Transformation of bacteria 
2.2.2.1. Chemical Transformation of E. coli 
E. coli DH5α or Dam- cells (only used when enzymes sensitive to methylation were 
subsequently used on plasmid DNA) were made chemically competent using the rhubidium 
chloride method. Briefly 2 mL of an overnight E. coli culture was inoculated into 200 mL 2 × 
TY ( tryptone and yeast extract, Appendix A) broth and incubated at 37 ºC with shaking at 
200 rpm until the cell density reached an OD600 = 0.5. This was then placed on ice for 15 min 
and the cells harvested at (3500 × g) for 5 min. The supernatant was discarded and 20 mL 
TfbI (transformation buffer I, Appendix A) was added per 50 mL culture volume, the pellet 
was gently resuspended and placed on ice for 15 min. Cells were harvested as indicated 
before, resuspended in 2 mL TfbII (transformation buffer II, Appendix A) per 50 mL culture 
volume and placed on ice for 15 min. Quick freeze in ethanol was carried out at -70 ºC, in 
500 µL aliquots, and stored at the same temperature. 
For the transformations, up to 1µg of plasmid DNA was added to 200 µL of competent cells 
(thawed on ice). This was chilled on ice for 15 min, thereafter heat shocked at 42 ºC for 90 
sec and placed on ice for 2 min. Following this, 700 µL LB was added to the transformation 
and the reaction was rescued at 37 ºC for an hour. Rescued transformations were plated on 
LA with the appropriate antibiotic/s and incubated overnight at 37 ºC. 
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2.2.2.2. Electroporation of E. coli 
Lucigen E. cloni 10F Supreme cells were used according to manufacturer’s instructions. 
Briefly, cuvettes were pre-chilled on ice and 25 µL competent cells (thawed on ice) were 
aliquoted into the cuvettes.  Thereafter, 1 µL sodium acetate precipitated ligation reaction or 
plasmid DNA (resuspended in 0.5× TE buffer) was added to the appropriate cuvette. After 
electroporation, 975 µL recovery medium was added to the cuvette following rescue of cells 
at 250 rpm for 1 hour at 37 ºC. Settings for electroporations were as follows: 600 Ohms 
resistance, 1800 V voltage, 10 µF capacity and a 1 mm cuvette. Plating was the same as for 
chemical transformation. 
2.2.2.3. Electroporation of M. smegmatis  
One hundred mL M. smegmatis culture was grown in 7H9 overnight at 37 ºC to OD600nm 0.5-
1.0. Cultures were incubated on ice for 30 min and thereafter transferred to chilled 50 mL 
conical tubes and spun down at 3500 rpm at 4 ºC for 10 min. The supernatant was discarded 
and pellet resuspended in 30 mL cold 10 % glycerol. Cells were spun down again and 
resuspended in 15 mL cold 10 % glycerol, followed by a third wash in 5 mL 10 % ice cold 
glycerol and stored on ice. Cells were used immediately. 
For electroporations, 400 µL of the competent cells were aliquoted into chilled 
electroporation cuvettes. Up to 1 µg of plasmid was added to the appropriate cuvette and 
incubated on ice for 5 min. Cells were electroporated and 1 mL 2 × TY was added to the 
cuvettes and the bacteria rescued overnight at 37 ºC. Electroporation settings were as follows: 
2500 v voltage, 1000 Ω resistance, 25 Ω capacity and 2 mm cuvette. After rescuing the cells, 
bacteria were harvested by centrifugation (3500 × g) for 10 min and resuspended in 400 µL 2 
× TY. Thereafter 10
1
-10
2
 dilutions were made and 100 µL of the dilutions, and the remainder 
of the undiluted cells, were plated on 7H10 with the appropriate antibiotic. Plates were 
incubated at 37 ºC for 3-5 days. 
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2.2.3. Plasmid preparation 
2.2.3.1. Plasmid Miniprep of E.coli (alkaline lysis method) 
For plasmid preparation, 2 mL overnight cultures grown in LA with the appropriate antibiotic 
were centrifuged (16500 × g) for 5 min. The cell pellets were resuspended in 100 µL cold 
Solution I (Appendix A), to which 200 µL Solution II (Appendix A) was added, inverted to 
mix, and placed on ice for 5 min. Thereafter 300 µL cold Solution III (Appendix A) was 
added, mixed by inversion, and incubated on ice for a further 5 min. Following incubation, 
the cell lysate was centrifuged (16500 × g) for 10 min and the supernatant was transferred to 
a sterile eppendorf tube, to which 2 µL RNase A was added. Tubes were incubated at 37 ºC 
for 20 min, followed by addition of 450 µL isopropanol to the tubes, which were mixed by 
inversion and centrifuged at 16500 × g for 20 min. The pellet was washed twice with 70 % 
ethanol and dried in the Eppendorf Concentrator 5301. The pellet was resuspended in 20 – 30 
µL sdH2O and quantified using the Nanodrop 1000 (Nanodrop technologies, USA). 
2.2.3.2. Plasmid Maxiprep of E. coli 
2.2.3.2.1. Alkaline lysis method 
For bulk preparation of plasmid DNA, 50 mL overnight cultures were centrifuged (3500 × g) 
for 10 min at 4 ºC and resuspended in 1mL cold Solution I, which was split into 200 µL 
aliquots and transferred to eppendorf tubes. The cells were harvested by centrifugation 
(16500 × g) for 30 seconds. The cell pellet was resuspended in 200 µL cold Solution I, 
followed by addition of 400 µL Solution II, mixing by inversion and incubation on ice for 5 
min. Thereafter, 300 µL cold Solution III was added, mixed and returned to ice for 10 min. 
The tubes were then centrifuged at 16500 × g for 10 min. The supernatant was transferred to 
a sterile eppendorf, to which 2 µL RNase (10 mg/mL) was added and incubated at 42 ºC for 
20 min. Thereafter, 650 µL isopropanol was added to each tube, allowed to cool at room 
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temperature for 10 min, followed by centrifugation for 20 min at 16500 × g. The DNA pellet 
was washed twice with 70% ethanol and dried in an Eppendorf Concentrator at 60 ºC for 15 
min. The pellet was resuspended in 200 µL sdH2O. For further purity, sodium acetate 
precipitation was used to clean the plasmid DNA as described in section 2.2.4.  
2.2.3.2.2. Bulk plasmid preparation using the Nucleobond Plasmid extraction kit  
In some cases, bulk plasmid preparations were made using the Nucleobond plasmid 
extraction kit, which was used according to the protocol provided by the manufacturer. 
Briefly, 50 mL of cells were harvested by centrifugation at 3500 × g for 15 min at 4 °C. Cells 
were resuspended in 8 mL Buffer S1 + RNase by vortexing and then lysed using 8 mL Buffer 
S2. Cells were neutralised by the addition of 8 mL Buffer S3 and the lysate cleared by 
centrifugation for 30 min at 3500 × g (4 °C). The cleared lysate was then loaded onto an 
equilibrated Nucleobond N100 column (equilibrated using Buffer N2), the flow through 
discarded and column was then washed twice with 10 mL Buffer N3 and flow through 
discarded. Plasmid DNA was eluted using 5 mL Buffer N5. The plasmid DNA was then 
precipitated by the addition of 0.8 volumes of isopropanol, followed by centrifugation, 
washing and quantification using the Nanodrop 1000. 
2.2.4. Sodium Acetate Precipitation 
For precipitation of DNA, 0.1 volume 3M sodium acetate buffer (pH 5.2) and 2 × volume 
cold 100 % ethanol was added to desired tube/s and mixed. Tubes were placed on ice for 20 
min and thereafter centrifuged (16500 × g) for 10 min. The pellet was then washed with 70 % 
ethanol, centrifuged for 5 min and dried in an Eppendorf Concentrator at 60 ºC for 15 min. 
The pellet was then resuspended in 20-40 µL TE or sdH2O. 
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2.2.5. Dephosphorylation of 5’ends 
For cloning, the vector is required to be dephosphorylated in order to reduce the possibility of 
the vector ligating to itself without the inclusion of the desired insert, leading to false 
positives. For this the Roche Fast AP phosphatase was used as per the manufacturer’s 
protocol (Roche, South Africa). Briefly, following restriction digest of the vector, 1 µL 
Roche Fast AP was added to the reaction along with 1/10 volume Fast AP buffer. The 
reaction was incubated at 37 ºC for a minimum of 2 hours. Reactions were heat inactivated at 
65 ºC for 15 min. 
2.2.6. Restriction analysis 
For restriction digest, up to 2 µg of DNA or plasmid was digested using 1 unit of the 
appropriate enzyme and 10 × buffer as per manufacturer’s instructions, in a 20 µL reaction. 
Enzymes used were from Roche, Fermentas (USA) or New England Biolabs (NEB, UK). 
NEB buffers were supplemented with 10 µg/mL BSA as required. 
2.2.7. Ligation Reaction 
For the ligation reactions, the vector:insert ratio was calculated using the following formula: 
                      
                               
                
 
Molar ratios of 1:1 or 1:2 were used, using 50 ηg of vector, as these produced the optimum 
results. T4 ligase from Fermentas was used according to manufacturer’s protocol using the 
appropriate calculated vector:insert concentrations in a 20 µL reaction. Reactions were 
incubated at room temperature for 30 min - 1 hour. For blunt cloning, PEG4000 was added to 
the reaction (1/10 volume), with an incubation time of 1 hour at room temperature. Reactions 
were then heat inactivated at 75 ºC for 15 min. 
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2.2.8. Agarose Gel Electrophoresis 
To resolve DNA, 0.8-1 % gels were used for high molecular weight fragments (>500 bp). 
Gels were made using 1× TAE (1 mM EDTA, 40 mM Tris-acetic acid pH 8.5) buffer, 
agarose and 0.5 µg/mL ethidium bromide. Gels were run at 80-100 voltage and DNA 
molecular weight markers were run alongside all samples. Gels were viewed under a UV 
light using the GeneSnap system (Biorad, South Africa). 
2.2.9. DNA extraction from Agarose Gels 
QIAquick gel extraction kit was used according to the provided protocol. Briefly, the agarose 
gel slice was weighed in a sterile eppendorf tube, to which thrice the volume of Buffer QG 
was added and this was incubated at 50 ºC until the gel slice was completely dissolved. Once 
dissolved, one volume isopropanol was added with this mixture being subsequently 
transferred to a QIAquick column in order to bind the DNA. The sample was centrifuged 
(17900 × g) for 1 min and flow-through discarded. The column was then washed by the 
addition of 750 µL Buffer PE, centrifuged (17900 × g) for 1 min, flow-through discarded and 
centrifugation repeated. The QIAquick column was then placed in a clean 1.5 mL eppendorf 
tube and DNA was eluted using 40 µL Buffer PE and quantified using the Nanodrop-1000. 
2.2.10. DNA Quantification 
Quantification of genomic DNA, plasmid DNA, as well as RNA was carried out using the 
Nanodrop ND-1000 Spectrophotometer (Nanodrop Technologies) which measures 
absorbance at 260 nm and 280 nm. Agarose gel electrophoresis was also used to quantify 
DNA by comparing the intensity of the desired bands against the intensity of the molecular 
weight markers used; Roche/Fermentas markers II, III and IV were used in this study 
(Appendix B).  
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2.2.11. DNA Sequencing 
Sequencing was outsourced to the Sequencing facility at Stellenbosch University, using the 
Big Dye terminator v3.1 Cycle Sequencing kit and Bioline Half Dye Mix. The sequencing 
data was analyzed using the Lasergene programme suite, specifically EditSeq and SeqmanTM. 
2.4. Library Preparation 
For genomic DNA libraries, 1 µg of DNA was digested by a serial dilution of the enzymes 
HpaII and AciI. An aliquot of the restriction digests were run on a 0.8 % gel and the 
fragments in the correct size range (0.5 kb – 3 kb) were excised and purified (as described 
above) followed by cleaning using a sodium acetate precipitation. pGADT7 was 
simultaneously restricted with ClaI, dephosphorylated, sodium acetate precipitated and 
dephosphorylated a second time. Ligation reactions were set up according to size differences 
between the vector and average size of insert. A 5.3 × concentration difference was used and 
a reaction was set up using 300 ηg of vector and 60 ηg of insert. The ligation reaction was 
incubated overnight at 22 ºC and was subsequently heat inactivated, sodium acetate 
precipitated and resuspended in 5 µL of 0.5 × TE buffer. Thereafter, 1 µL of this reaction was 
used for electroporation into Lucigen E. cloni 10F Supreme cells (as previously described) 
and plated on LA/Amp. Plates were incubated overnight at 37 ºC and 10 colonies were 
picked, a plasmid miniprep was carried out and the plasmid was digested with HinDIII to 
ensure presence of insert. The rest of the cells were then scraped into LB media. An aliquot 
was frozen at -80 ºC and plasmid isolation was carried out using the Nucleobond kit for the 
remainder of the cell mixture. Purified plasmid was stored at – 20 ºC until further use. 
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2.5. Polymerase Chain Reaction (PCR) 
2.5.1. Roche Fast Start PCR 
Screening/ confirmation of M. smegmatis clones were achieved by using the appropriate 
primers in a Roche FastStart PCR reaction. A 30 µL reaction was set up using 8 µL 10 mM 
dNTPs, 3 µL 10× PCR buffer with MgCl2, 6 µL 5× GC rich solution, 2.5 µL 10 mM forward 
primer, 2.5 µL 10 mM reverse primer, 0.5 µL FastStart Taq Polymerase, up to 5 µL template 
DNA, and sdH2O up to 30 µL. Cycling conditions were as follows: one cycle of an initial 
denaturation at 94° C for 4 min; 30-35 cycles of 30 s denaturation at 94° C, 30 s annealing at 55-
70° C and 30-90 s elongation at 72° C which was followed by a final elongation step at 72° C for 
5-7 min. 
2.5.2. Phusion High Fidelity PCR 
Amplification of genes for cloning was carried out using Phusion high fidelity PCR. A 50 µL 
reaction was set up using 10 µL 5 × HF buffer, 1.5 µL DMSO, 8 µL 10 mM dNTPs, 2.5 µL 
10 mM forward primer, 2.5 µL 10 mM reverse primer, 0.3 µL Phusion Taq Polymerase, 
DNA up to 0.1 µg, and sdH2O up to 50 µL. Cycling conditions were as follows for 35 cycles: 
initial denaturation at 98 ºC for 3 min, denaturation at 98 ºC for 10 s, annealing between 55 
ºC-70 ºC for 30 s, elongation at 72 ºC for 45 s and final elongation at 72 ºC for 7 min. 
2.5.3. PCR clean up 
QIAquick PCR clean-up kit was used according to the provided protocol. Briefly, 5 volumes 
buffer PBI was added to 1 volume of the PCR sample, mixed, and transferred to a QIAquick 
column. In order to bind the DNA, sample was then centrifuged (17500 × g) for 1 min and 
flow-through discarded. Thereafter, 750 µL buffer PE was added to the column and 
centrifugation step was repeated twice. Column was then placed in a clean 1.5 mL eppendorf 
tube and DNA was eluted using 40 µL buffer EB. DNA was subsequently quantified using 
the Nanodrop-1000. 
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2.6. Cloning 
2.6.1. 3-way cloning 
The dacB gene and MSMEG_2433 were cloned either with mCherry, rsEGFP or Venus into 
pSE100. Primers used for amplification of genes are outlined in Table 2.3. The vector, 
pSE100, was restricted with PacI and PstI for the dacB and mCherry cloning, PacI and 
HinDIII for dacB and Venus cloning, as well as for the MSMEG_2433 and Venus cloning, 
BamHI and HinDIII for dacB and rseGFP cloning, and finally, PstI and HinDIII for the 
MSMEG_2433 and rsEGFP cloning. pSE100 was digested, dephosphorylated and fragments 
were digested with enzymes indicated above. These were then run on a 0.8 % gel; the 
fragments were excised and extracted using the Nucleospin gel extraction kit. Cloning was 
achieved using a ligation ratio of 1:2:2 (pSE100: gene: fluorescent gene). Ligations were 
transformed into E. coli DH5α and plated on LA + Hyg. Potential positive clones were 
screened by restriction analysis and one putative clone was taken forward by inoculation into 
50 mL LA + Hyg and plasmid maxiprep was achieved using the Nucleobond kit. The plasmid 
was then electroporated into M. smegmatis, plated on 7H10 + Hyg and incubated at 37ºC for 
3 days. A colony was picked and small scale DNA extraction was carried out followed by 
confirmation using PCR (with primers of the appropriate genes). The repressor pMC1s was 
electroporated into electrocompetent M. smegmatis carrying pSEdacB-rsEGFP and confirmed 
using PCR with the pMC1s primers (Appendix C). Freezer stocks of all clones were made 
using 33 % glycerol and stored at -70 ºC. 
2.6.2. Blunt-end cloning of DD-CPase-GFP fusions 
For cloning of the blunt ended dacB-rsEGFP cassette, with the tetO, the cassette was cut out 
of the pSE100 background using PciI and HinDIII. The fragment ends were blunted using the 
Klenow fragment from NEB, as well as Polymerase I (NEB), according to the manufacturer’s 
instructions. Briefly, a 30 µL reaction was set up using the 20 µL restriction digest, 3 µL 10 
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mM dNTPs, 3 µL NEB buffer 2 with BSA, 1 µL Klenow fragment (NEB), 1 µL T4 
Polymerase I (NEB) and sdH2O up to 30 µL. The reaction was incubated at 22 ºC for 15 min. 
pTweety was restriction digested with SmaI and dephosphorylated using FastAP. Blunt 
cloning was followed using a ligation insert:vector ratio of 1:2. Ligations were transformed 
into E. coli DH5α and plated on LA + Genta. Potential positive clones were screened by 
restriction analysis (using XbaI) and one clone was taken forward by inoculation into 50 mL 
LA + Genta. Plasmid maxiprep was achieved using the Nucleobond kit. The resulting 
plasmid, as well as the repressor pMC1s was then electroporated into M. smegmatis, plated 
on 7H10 + Genta for the plasmid only, and 7H10 + Genta + Kan for the plasmid with 
pMC1s, and incubated at 37ºC for 3 days. A colony was picked and small scale DNA 
extraction was carried out and vector incorporation was confirmed using PCR (with primers 
of the appropriate genes as well as primers for pMC1s). Freezer stocks of all clones were 
prepared. 
Table 2.3. Primers used for 3-way cloning 
Gene Primer (5’ – 3’) 
dacB (mCherry) F 
dacB (mCherry) R 
GCGCTTAATTAA
PacI
ATGAGCGATAGGCTGACG 
GCGCGGATCC
BamHI
TGCGCCGCATCCGCAGCT 
dacB (Venus) F 
dacB (Venus) R 
GCGCTTAATTAA
PacI
ATGAGCGATAGGCTGACG 
GCGCAGATCT
BglII
TGCGCCGCATCCGCAGCT 
dacB (rsEGFP) F 
dacB (rsEGFP) R 
GCGCGGATCC
BamHI
ATGAGCGATAGGCTGACG 
GCGCGAATTC
EcoRI
TGCGCCGCATCCGCAGCT 
2433 (Venus) F 
2433 (Venus) R 
GCGCTTAATTAA
PacI
ATGTGGAGGTACGCCTTC 
GCGCAGATCT
BglII
GAGCGCCCCGATGCTCGC 
2433 (rsEGFP) F 
2433 (rsEGFP) R 
GCGCCTGCAG
PstI
ATGTGGAGGTACGCCTTC 
GCGCGAATTC
EcoRI
GAGCGCCCCGATGCTCGC 
mCherry F 
mCherry R 
GCGCGGATCC
BamHI
ATGGCTTCCTCCGAAGAC 
GCGCCTGCAG
PstI
TTATTAAGCACCGGTGGA 
Venus F GCGCAGATCT
BglII
ATGGTTTCAAAGGGTGAA 
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Venus R GCGCAAGCTT
HinDIII
TTATTACTTGTATAATTC 
rsEGFP F 
rsEGFP R 
GCGCGAATTC
EcoRI
ATGGTGAGCAAGGGCGAG 
GCGCAAGCTT
HinDIII
TTACTTGTACAGCTCGTC 
Restriction enzyme sites are underlined. 
2.7. Microscopy 
2.7.1. Fluorescence Microscopy 
Cells were prepared by growing a 5 mL culture in 7H9 supplemented with the appropriate 
antibiotic at 37 ºC overnight, to an OD600nm = 0.3 – 0.5. The culture was centrifuged (3500 × 
g) for 10 min (4 ºC). The pellet was resuspended in 1 mL 7H9 and transferred to a sterile 
eppendorf tube. Cells were spun down, harvested at 16500 × g for 5 min and washed twice 
with 400 µL 7H10. Cells were then resuspended in 50 µL 7H9. For staining, following the 
initial spin step, 1 µg/mL vancomycin (cold) and 1 µg/mL fluorescent vancomycin (BODIPY 
label) was added to the resuspended pellet and incubated at 37 ºC for 1.5 hours.  
A 2 % agarose gel was used to prepare a pad where approximately 250 µL of gel mix was 
spread onto a slide. Another slide was placed over in order to ensure an even surface. The top 
slide was removed and 2 - 5 µL of cells were spread onto the agarose bed and a cover slip 
placed over. Slides were viewed immediately on the Zeiss LSM-780 Confocal microscope 
and images processed with ZEN black Ver. 11 software (Zeiss, Germany). 
2.7.2. Immunogold and Transmission Electron Microscopy (TEM) 
pSEdacB-rsEGFP and pSE2433-rsEGFP cells were scraped off 7H10/Hyg plates and fixed 
using 4 % paraformaldehyde and 0.5 % glutaraldehyde in PBS (pH 7.4) at 4 ºC for 4 hours. 
Cells were centrifuged at 3500 × g for 10 min (4ºC), the pellet was washed with PBS and 
centrifuged again followed by resuspension in 4 % low melting agarose and subsequently 
allowed to set on ice. Cubes of approximately 1 mm
3
 were then cut, washed with PBS and 
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thereafter washed with sdH2O. Samples were then dehydrated through a graded series of 
ethanol as follows; 50 % ethanol at 4 ºC for 10 min, 75 % ethanol at 4 ºC for 10 min, 95 % 
ethanol at 22 ºC for 10 min and 100 % ethanol at 22 ºC for 30 min. A 1:1 mixture of LR 
white:100 % ethanol was added and mixed for 1 hour. The mixture was poured out and 100 
% LR white was added and mixed overnight (on a Rotamix) at 4 ºC. The resin was replaced 
with 100 % LR white and mixed at room temperature for 1 hour. Samples were then 
embedded in Beem capsules and polymerized at 50 ºC for 24 - 36 hours. Ultrathin sections 
were cut using Relchert Ultracut Ultramucrotome (Circa Scientific, Canada) and mounted onto 
formvar-carbon coated nickel grids and allowed to dry overnight. 
Subsequent immunolabelling was performed by incubating the grids in small reagent droplets 
on parafilm at room temperature. The free aldehyde was quenched by incubating the grids in 
0.1 M glycine solution for 20 min. Sections were then rinsed twice using TBS-Tween for 2 
min and were subsequently incubated in blocking buffer for 30 min, thereafter on droplets of 
primary antibody (1:50, 1:100, or 1:500 dilution) for 2 hours at room temperature. Sections 
were rinsed, 6 times, on droplets of TBS-Tween for 2 min. Sections were then rinsed on 
droplets of 1:50 dilution of secondary antibody for 1 hour at room temperature and rinsed 
again on large droplets of TBS-Tween, 6 times for 2 min. Slides were then dried completely 
prior to fixing. Post-fixation of sections were then carried out on droplets of 2 % 
glutaraldehyde in 0.1 M PBS for 10 min and followed by rinsing 6 times with TBS-Tween 
for 2 min. Sections were then rinsed in 3 × 20 dips of sdH2O and subsequently stained with 
uranyl acetate for 5 min and lead citrate for 5 min. Grids were viewed using a Tecnai F20 
TEM. 
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2.8. Minimum Inhibitory Concentration (MIC) Determination 
Wild type M. smegmatis, ∆MSMEG_1661, ∆MSMEG_2433 and ∆MSMEG_2432 were 
grown in 7H9 at 37 ºC to an OD600nm of 0.3. A 1:10 dilution of the cultures was carried out, 
which was then diluted a further 1:50. The experiment was set up using a 96 well plate with 
the broth microdilution method (Domenech et al., 2005). The following antibiotics were 
used: Ampicillin (Amp), Vancomycin (Vanc), Erythromycin (Ery), Rifampicin (RIF), 
Cefamandole (Cad), Cefoxitin (Cox), Cefotaxime (Cot), Ceftriaxone (Ctx) and Cefapirin 
(Cap). Plates were incubated at 37 ºC for 5 days and thereafter viewed visually with the MIC 
being determined as the lowest drug concentration which inhibited growth by 90 %. 
2.9. Assessment of growth and Gene Expression  
2.9.1. Growth Curves 
A 5 mL pre-culture of M. smegmatis mc
2
155 (pSEdacB-rsEGFP), i.e. repressor-less (R-), and 
pSEdacB-rsEGFP::pMC1s 0 ηg tet, including repressor (R+), were started from freezer 
stocks, which was then used to inoculate a 30 mL pre-culture. This 30 mL culture was then 
used to inoculate 150 mL cultures of (i) R-; (ii) R+ supplemented with 0 ηg AHT; (iii) R+ 
supplemented with 0.5 ηg AHT; (iv) R+ supplemented with 5 ηg AHT; (v) R+ supplemented 
with 50 ηg AHT; and (vi) R+ supplemented with 100 ηg AHT, at an OD600nm of 0.02. 
Samples were taken at 6 hours, 9 hours and 18 hours (i.e. from early to mid-log growth) from 
which OD600nm readings, fluorescent microscopy and quantitative PCR was carried out. 
2.9.2. RNA Isolation 
For preparation of RNA for gene expression analysis, 50-100 mL aliquots of culture were 
spun down for 10 min at 3500 × g. The cells were resuspended in 1 mL 7H9, spun down 
again and resuspended in 500 µL 1 × TE buffer. Thereafter, 50 µL lysozyme (10 mg/mL) was 
added to each tube and incubated at 37 ºC for 30 min. The cultures were then aliquoted into 
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ribolyzing tubes and ribolyzed at a speed of 4.0 for 45 seconds and placed on ice for 2 min. 
The ribolyzing step was repeated thrice. The supernatant was transferred to an eppendorf 
tube, to which 355 µL lysis buffer was added, vortexed and stored at -80 ºC until RNA 
isolation. RNA isolation was carried out according to the Nucleospin RNA II kit according to 
the protocol. Briefly, the lysate was filtrated, to which 350 µL 70 % ethanol was added. 
Samples were then loaded onto a column to bind RNA and centrifuged at 11000 × g for 30 
seconds. The silica membrane was desalted by the addition of 350 µL membrane desalting 
buffer and centrifugation at 1000 × g for 1 min. DNA digestion was then carried out using 95 
µL DNase (made up of 10 µL rDNase reconstituted as per manufacturer’s instructions) 
reaction mixture and incubated at room temperature for 15-30 min. The silica membrane was 
washed initially with 200 µL RA2, centrifuged at 11000 × g for 30 seconds, thereafter with 
600 µL RA3, centrifuged and 11000× g for 30 seconds, and finally with 250 µL RA3, 
centrifuged at 11000 × g for 2 min. RNA was then eluted with 50 µL RNase free H2O and 
quantified using the Nanodrop. One µg of RNA was then treated with DNase1 using 1 µL 
Turbo DNase, incubated at 37 ºC for 30 min, followed by the addition of another 1 µL Turbo 
DNase and 30 min incubation. DNase inactivation was carried out using 7 µL DNase removal 
resin and centrifuged at 13000 rpm for 5 min. A 23 µL volume of the sample was then 
removed and used for RT-PCR. 
2.9.3. Reverse Transcriptase (RT) synthesis 
A 2.5 µM reverse primer mix of dacB and sigA reverse primers were made up and 2 µL was 
added to the Turbo DNase treated RNA. The sigA gene was included as a normalizer since 
expression of this house keeping gene remains consistent throughout growth. Reactions were 
run as follows: 94 ºC for 30 seconds, 65 ºC for 3 min and 57 ºC for 3 min. RT+ and RT- 
reactions were set up using SuperScript III according to the manufacturer’s protocol. Briefly, 
a 25 µL reaction was set up using 5 µL first strand  buffer, 4 µL 25 mM MgCl2, 2 µL 0.1 M 
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DTT, 1 µL 10 mM dNTPs and 0.8 µL SuperScript III, to which 12.5 µL of the annealed 
product was added. A RT negative control was set up that excluded the SuperScript III, 
which was replaced with sdH2O. Reactions were placed in the PCR machine, incubated at 50 
ºC for 50 min and inactivated at 85 ºC for 5 min, the resulting cDNA was then taken forward 
for qPCR. 
2.9.4. Quantitative Real Time PCR (qPCR) 
qPCR was carried out using the SsoFast Evergreen Supermix (Biorad). For this, 20 µL 
reactions were set up using 10 µL SsoFast Evergreen Supermix, 0.75 µL forward primer (10 
µM), 0.75 µL reverse primer (10 µM), 1 µL cDNA and 7.5 µL sdH2O. A standard curve was 
also set up using the same reaction, with the addition of 2 µL genomic DNA instead of 
cDNA. Reactions were placed into a CFX96 Real-Time PCR detection system (Bio-Rad 
Laboratories) and carried out with two sets of reactions with the following cycling 
parameters: The first set commences with an enzyme activation step of 95 ºC for 30 s, 
followed by, ten cycles of denaturation at 95 ºC for 10 s, touchdown annealing commencing 
at 65 ºC for 10 s and decreasing by 0.5 ºC following each cycle, and finally elongation at 72 
ºC for 10 s. Thereafter, the second set of reactions consisting of 35 cycles commences as 
follows: a denaturation step at 95 ºC for 10 s, an annealing step at 60 ºC for 10 s and an 
elongation step at 72 ºC for 10 s. Thereafter, melt curve analysis was conducted from 50 ºC 
and gradually increasing to 95 °C. N.B. SYBR Green quantification was carried out 
following each cycle at all stages. 
2.10. Southern Blot  
2.10.1. Probe synthesis 
DIG-dUTP labelled probes were synthesized using a DIG-dNTP mix in a Roche FastStart 
PCR reaction. Briefly, a 50 µL reaction was set up using 5 µL 10 × PCR buffer with MgCl2, 
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10 µL 5 × GC rich solution, 2.5µL 10 mM forward primer (dacB), 2.5µL 10 mM reverse 
primer (dacB), 5 µL DIG-dNTP mix or 8 µL 10 mM dNTPs for the negative control or a 
mixture of both as an extra control, 0.5 µL FastStart Taq Polymerase, 50 ηg template DNA, 
and sdH2O up to 50µL. Cycling conditions were as previously described in section 2.5.1. 
Reaction and controls were run on the same agarose gel as a molecular weight shift is caused 
by DIG-labelling. 
2.10.2. Blotting 
Restriction digests of 500 ηg of chromosomal DNA using 2 U of the enzymes BclI and StuI 
were carried out overnight at 37 ºC. These were run on a 0.8 % agarose gel with Roche 
marker IV for 2 hours at a voltage of 80 v. The gel was photographed using the G-Box 
SYNGENE system and was thereafter depurinated in 0.2 M HCl solution for 10 min with 
gentle shaking. Gels were then denatured in 0.5 M NaOH/ 1.5 M NaCl for 30 min with gentle 
shaking. Gels were washed in 1 × TBE buffer (89 mM Tris Borate, 2 mM EDTA, pH 8.3), 
overlaid with Hybond
TM
-N nitrocellulose membrane and thereafter sandwiched between 2 
thick Whatman filter papers and 2 pre-soaked sponges (in 1 × TBE) in a gel cassette. This 
was transferred to an SB10 tank (Bio-Rad) containing 1 × TBE. DNA transfer to the 
nitrocellulose membrane was carried out for 2 hours at 600 mA. Crosslinking was carried out 
by UV irradiation at 2500 mJ/cm
3
 twice. Membrane/s were then added to hybridization 
bottles containing 12 mL DIG-EASY-HYB and incubated at 54 ºC for 30 min. The probe was 
then denatured at 95 ºC for 5 min and added to the DIG-EASY-HYB in the bottle. 
Hybridization was carried out at 54 ºC overnight. The membrane was then washed with 20 
mL solution I (2 × SSC, 0.1 % SDS) by gentle tilting for 5 min, and thereafter washed twice 
with pre-warmed solution II (0.5 × SSC, 0.1 % SDS) at 68 ºC for 15 min in the hybridization 
oven. The membrane was then rinsed in washing buffer (0.1 M maleic acid buffer, 0.3 % 
Tween20) for 5 min, incubated in 20 mL blocking solution (1:10 dilution of 10 × blocking 
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solution in 0.1 M maleic acid buffer) for 30 min at room temperature, incubated in 20 mL 
Antibody solution (20 mL 1 × blocking solution, 2 µL Anti-DIG-AP) for 30 min at room 
temperature, washed twice in wash buffer for 15 min and finally equilibrated for 5 min in 20 
mL detection buffer. The membrane was placed in a hybridization bag and 1 mL CSPD was 
spread over the membrane. The membrane was then incubated at 25 ºC for 5 min, excess 
liquid was squeezed out  and incubated at 37 ºC for 10 min. Membranes were then exposed to 
X-ray film for 30 min and developed in an automated Axim developer. 
2.11. Yeast 2-Hybrid system 
2.11.1. Cloning of bait for yeast interaction libraries  
The dacB gene and MSMEG_2433 were amplified by Phusion high fidelity PCR using the 
following primers, GCGCGGCGCCATATAG
NdeI
CGATAGGCTGACG & 
GCGCCGGGATCC
BamHI
TCATGCGCCGCATCCGCA; 
GCGCGGCGCCATATG
NdeI
TGGAGGTACGCCTTC & 
GCGCCGCTGCAGTCAG
PstI
AGCGCCCCGATGCT respectively. pGBKT7 was digested 
with NdeI and BamHI for dacB cloning, and PstI and NdeI for MSMEG_2433 cloning and 
thereafter dephosphorylated. Ligation reactions were followed using an insert:vector ratio of 
1:2. Transformations and plasmid preparations were followed as previously described in 
sections 2.2.2 and 2.2.3. 
2.11.2. Yeast transformation  
2.11.2.1. Bait construction 
Several 1-3 week Y187 colonies (approximately 2.5 mm in diameter) were inoculated into 1 
mL YPDA media, vortexed and transferred to a flask containing 50 mL YPDA. This was 
incubated at 30ºC for 16-18 hours shaking at 250 rpm to OD600nm =1.80 – 2.00. The overnight 
culture was subsequently transferred to 300 mL YPDA, the cell density adjusted to an 
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OD600nm = 0.25 and incubated at 30ºC for 3 – 4 hours, shaking at 230 rpm, to OD600nm = 0.5 ± 
0.1. Cells were transferred to 50 mL Falcon tubes and centrifuged at 1000 × g for 5 min at 
22ºC. Cells were washed twice with sdH2O and thereafter each 50 mL Falcon tube pellet was 
resuspended in 5mL sdH2O, pooled, and centrifuged at 1000 × g for 5 min at 22ºC. The 
supernatant was discarded and cell pellet was resuspended in 1.5 mL freshly prepared 1 × 
TE/LiAC. 
For the transformation, 0.1 µg of the bait (dacB or MSMEG_2433) and 0.1 mg Herring testes 
carrier DNA were added to 1.5 mL eppendorf tubes, to which 100 µL prepared yeast 
competent cells were added and vortexed. Following this, 600 µL freshly prepared 
PEG/LiAC solution was then added to the tubes and vortexed to mix. Reactions were then 
incubated at 30 ºC for 30 min with shaking at 200 rpm. Thereafter 70 µL DMSO was added 
and mixed gently by inversion. This was then heat shocked for 15 min at 42 ºC. Reactions 
were then placed on ice for 2 min and centrifuged for 30 seconds at 16500 × g. Cells were 
resuspended in 500 µL 1 × TE buffer, 100 µL was plated on SD/-Trp and incubated at 30 ºC 
for 3 – 5 days. 
2.11.2.2. Autoactivation 
To test for autonomous histidine activation, a transformation reaction was carried out as for 
the bait, with the addition of 0.1 µg empty pGADT7 (prey) with the 0.1 µg bait. Following 
resuspension, 100 µL aliquots of cells were plated on SD/-Leu, SD/-Trp and SD/-Leu/-Trp 
dropout media. Colonies that emerged on SD/-Leu/-Trp were picked and resuspended in 500 
µL 1 × TE buffer. The OD600nm was adjusted to 0.5 and 10 µL was spotted on SD/-Leu/-Trp, 
SD/-Leu/-Trp/-His, SD/-Leu/-Trp/-His + 0.5 mM 3AT, SD/-Leu/-Trp/-His + 1 mM 3AT and 
SD/-Leu/-Trp/-His + 1.5 mM 3AT. Plates were incubated at 30 ºC for 3 - 5 days. 
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2.11.2.3. Construction of yeast library of M. smegmatis genomic fragments  
AH109 was made competent using the same procedure as for Y187 (section 2.11.2.1), but up-
scaled to library scale. Briefly, the overnight culture was transferred to 1 L YPDA and 
resuspended in 8 mL freshly prepared 1 × TE/LiAC. For the transformation, 0.3-0.4 mg 
sodium acetate precipitated library DNA and 20 mg Herring testes carrier DNA (denatured) 
was added to a 500 mL flask to which 8 mL AH109 competent cells was added and mixed 
vigorously. Then, 60 mL freshly prepared PEG/LiAC was added and vortexed to mix. This 
was incubated at 30 ºC for 30 min with shaking at 200 rpm, 7 mL DMSO was added and 
mixed by gentle swirling, heat shocked at 42 ºC for 15 min in a water bath and chilled on ice 
for 2 min. Cells were then centrifuged at 1000 × g for 5 min and the pellet was resuspended 
in 10 mL 1 × TE buffer. Thereafter, 200 µL aliquots were plated on approximately 55 SD/-
Leu plates and incubated at 30 ºC for 3 - 5 days. Plates were scraped into freezing media 
(YPDA + 25 % glycerol), transferred to 2 mL cryovials and placed at -80 ºC. 
2.11.3. Yeast Mating 
One fresh 2-3 mm colony of transformed bait (dacB cloned into Y187 or MSMEG_2433 
cloned into Y187) was inoculated into 50 mL SD/-Trp media and incubated shaking (250 
rpm) at 30 ºC overnight to an OD600nm = ~0.8. Cells were centrifuged at 1000 × g for 5 min 
and the pellet was resuspended in 3.5 - 4 mL SD/-Trp to a cell density of >1×10
8
 cells/mL. 
An aliquot of the M. smegmatis library was thawed in a room temperature water bath and a 
1:100 dilution made to obtain a cell density of >2×10
7
 cells/mL. The library was combined 
with the bait strain in a 2 L flask, to which 45 mL of 2 × YPDA supplemented with Kan was 
added. The flask was then incubated at 30 ºC for 24 hours, shaking at 40 rpm. Following 
incubation, a drop of the culture was viewed under the Zeiss phase contrast microscope (40×) 
to check for the formation of zygotes. Cells were transferred to 50 mL conical tubes and 
centrifuged at 1000 × g for 10 min. The 2 L flask was rinsed twice with 25 mL 0.5 × YPDA 
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supplemented with Kan and this was used to resuspend the cell pellet from the previous step. 
The cells were centrifuged at 1000 × g for 10 min and the resulting pellet was resuspended in 
10 mL 0.5 × YPDA/Kan media. Thereafter, 10
1
 to 10
4
 dilutions were made and 100 µL of 
each was plated on SD/-Trp, SD/-Leu and SD/-Leu/-Trp. The remainder was plated in 200 
µL aliquots on SD/-Leu/-Trp/-His. All plates were incubated at 30 ºC for 6 days. All colonies 
which grew on SD/-Leu/-Trp/-His were picked, resuspended in 200 µL 0.5 × YPDA and 
spotted on SD/-Leu/-Trp, SD/-Leu/-Trp/-His/X-α-Gal and SD/-Leu/-Trp/-His/-Ade. Colonies 
which were blue on SD/-Leu/-Trp/-His/X-α-Gal were picked, resuspended in 500 µL 0.5 × 
YPDA, OD600nm adjusted to 0.1 and 10 µL was spotted on SD/-Leu/-Trp/-His/X-α-Gal, SD/-
Leu/-Trp/-His/-Ade and SD/-Leu/-Trp/-His/-Ade/X-α-Gal. Plates were incubated at 30 ºC for 
6 days. 
2.11.4. Plasmid Isolation from Yeast 
Potential positive clones were picked and grown in 2 mL SD/-Leu (to select for the prey) 
overnight at 30 ºC. Cells were spun down at 16000 × g for 1 min and the supernatant was 
discarded. The cell pellet was resuspended in 230 µL DNA lysis buffer (10 mM Tris HCl, 0.1 
M NaCl, 1 % SDS, 1 mM EDTA, 2 % Triton X-100). The suspension was transferred to a 
screw cap tube containing 0.4 g acid-washed 0.75 – 1 mm glass beads, to which 200 µL 
phenol:chloroform:isoamyl alcohol (25:24:1) was added. Tubes were vortexed at top speed 
for 2 min to isolate the plasmid DNA and thereafter spun down at 16000 × g for 5 min. The 
top aqueous layer was transferred to a sterile eppendorf tube and sodium acetate precipitation 
was followed. The pellet was resuspended in 30 - 40 µL 0.5 × TE buffer. 
2.11.5. Transformation into E. coli 
One µL of the isolated plasmid DNA isolated from yeast was electroporated into Lucigen E. 
cloni 10F Supreme cells as previously described, with the entire transformation being plated 
on LA/Amp and incubated overnight at 37 ºC. 
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2.11.6. Zyppy
TM
 Plasmid Miniprep 
One colony from each successful electroporation was picked and grown in LB/Amp 
overnight at 37 ºC. Zyppy plasmid miniprep was followed according to the provided protocol. 
Briefly, 2 mL of the E. coli culture was spun down at 16500 × g for 5 min and the pellet was 
resuspended in 600 µL LB, to which 100 µL 7 × lysis buffer was added and inverted 6 - 8 
times to mix. Thereafter, 350 µL cold neutralization buffer was added, mixed by flicking, and 
centrifuged at 16500 × g for 2 min. The supernatant was transferred to a Zymo-spin
TM
 
column and centrifuged for 15 seconds. Two hundred µL of Endo-wash buffer was added to 
the column and centrifuged for 15 seconds. Thereafter 400 µL Zyppy
TM
 wash buffer was 
added to the column and centrifuged for 30 seconds (16500 × g). The column was then 
transferred to a clean eppendorf tube and 30 µL Zyppy
TM
 elution buffer was added to the 
column, incubated at room temperature for 2 min and thereafter centrifuged at 16500 × g for 
30 seconds. Plasmid DNA was sent for sequencing using the T7 region primers. 
2.11.7. Confirmations 
Sequences from positive clones were analyzed using the NCBI website, namely nucleotide 
BLAST (BLASTn) and subsequently protein BLAST (BLASTx) in order to determine the 
presence and identity of any interacting proteins. Once potential interactions were found, the  
small scale yeast transformations using 100 ηg of vector into AH109 were carried out using a 
combination of either pGBKT7/bait (MSMEG_2433 or dacB) + pGADT7/prey (potential 
interacting partner); or empty pGBKT7 + pGADT7/prey. pGADT7 and pGBKT7 vector only 
were also transformed as controls. These were subsequently plated on SD/-Leu/-Trp, SD/-
Leu/-Trp/X-α-Gal, SD/-Leu/-Trp/-His, SD/-Leu/-Trp/-His/X-α-Gal, SD/-Leu/-Trp/-His/-Ade, 
SD/-Leu/-Trp/-His/-Ade/X-α-Gal and incubated at 30 °C for 6 days.  
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3. Results 
3.1. Library Preparation 
3.1.1. Genomic DNA 
For construction of the library, a high concentration of genomic DNA was required in order 
to obtain enough fragments for full coverage. Hence, a stationary phase culture of M. 
smegmatis was used for DNA isolation, which resulted in a high yield of genomic DNA that 
was not sheared and ran at a molecular weight > 20 kb, Figure 3.1. 
 
Figure 3.1. Agarose gel of extracted genomic DNA from WT M. smegmatis. [Lane 1] Roche Marker III, 
[Lanes 2-13] Isolated M. smegmatis genomic DNA. 
 
A variety of enzymes including HinDIII, BglII, SacI, BamHI and ClaI were utilized to digest 
genomic DNA, with the enzymes SacI and BglI showing the best frequency in cutting for the 
construction of a library (moderate cutters – data not shown), while BamHI showed a high 
frequency of cutting, indicating that a partial digestion would yield appropriately sized 
fragments as well. The vector into which this DNA was cloned (pGADT7) contained unique 
restriction sites for proper insertion of the fragments, which included the BamHI site, as well 
as the ClaI site, for constructing fusions with a HpaII/AciI digested genomic DNA library 
(James et al., 1996). Considering the previously published M. smegmatis genomic libraries in 
21226
5148
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yeast vectors, we decided to use the ClaI site for pGADT7 linearization and HpaII/AciI for 
fragment preparation (Steyn et al., 2002). 
3.1.2. Vector and Fragment Preparation 
The prey vector (pGADT7) was transformed into Dam- E. coli cells and the plasmid was 
isolated. The vector was subsequently digested using ClaI in order to linearize the vector, 
which was then phosphatased in order to prevent vector re-ligation. The linearized vector is 
shown in Figure 3.2. 
 
Figure 3.2. Agarose gel of pGADT7. [Lane 1] Roche Marker II, [Lanes 2, 4, 5] Empty, [Lane 3] Uncut 
pGADT7, [Lanes 6-8] ClaI digested pGADT7. 
 
Restriction of pGADT7 with ClaI resulted in linearization of the vector as expected, Figure 
3.2. A ligation control was carried out to assess vector re-ligation background colonies 
following phosphatase treatment. A negligible number of vector re-ligation products were 
obtained (data not shown). The linearized product was then taken forward for library 
preparation. 
M. smegmatis DNA fragments for cloning were obtained with either HpaII or AciI restriction 
digest using an enzyme dilution series. A range of 500-5000 bp was chosen, Figure 3.3. 
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Figure 3.3. Agarose gels of genomic DNA restrictions. (A) HpaII restriction by using a 3 fold dilution series of 
the enzyme [Lane 1] Roche Marker IV, [Lanes 2-7] HpaII restriction of genomic DNA at each dilution. (B) 
AciI restriction by using a 3 fold dilution series of the enzyme [Lane 1] Roche Marker IV, [Lanes 2-7] AciI 
restriction of genomic DNA at each dilution. 
 
Initial attempts at construction of the library were not met with success. Many different 
methods were attempted to optimize the approach and obtain a high enough efficiency. HpaII 
and AciI restrictions were ligated separately with ligations set up to target a range of sizes: 
500 bp; 2500 bp and 5000 bp. However the highest efficiency reached was 10
4
 CFU/mL, 
which was insufficient for full coverage (we required at least 10
5
 - 10
6 
CFU/mL). 
Transformation efficiency calculation is shown in Appendix D. Transformations were carried 
out with chemically competent cells prepared freshly using a variety of approaches. However, 
this did not improve efficiency (data not shown).  
Commercially available E. coli chemically competent cells were then used, which retained an 
efficiency of > 2 × 10
8
 CFU/mL on purified plasmid DNA. When this did not work, vector 
and fragments were prepared in bulk and the ligase was heat inactivated following the 
ligation reaction. Efficiency still did not improve. The AciI and HpaII fragments were then 
combined into one reaction and T4 ligase was replaced with FastLink DNA ligase. A bulk 
ligation was then attempted and all reactions pooled together and dried but the efficiency 
remained low. Fragments were then concentrated using sodium acetate and ethanol 
(fragments were run on a gel to confirm their presence). A 1:3 vector:insert ratio was then 
attempted using 1µg of vector. The results revealed that only the 500 bp targeted reaction 
1 2          3          4          5           6         7
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gave a 10
4
 CFU/mL efficiency, while the 2500 bp and 5000 bp reactions resulted in 
negligible efficiencies (< 10 CFU/mL), as fewer colonies were observed than the background 
for the above-mentioned reactions. This was attributed to the large size of the fragments in 
latter ligations. Thus, a 1:3 ratio was followed for the 500 bp and 1:1 for the 2500 bp and 
5000 bp targeted reactions. Whilst the efficiencies improved, they remained at 10
3 
- 10
4 
CFU/mL. The ligations were then repeated, but this time using fragments in the range of 500-
3000 bp with ligations targeted to 1000 bp and 3000 bp in a 1:1 ratio. The efficiency 
remained at 10
4
 CFU/mL. Takara ligase was then used and electroporation was carried out 
instead of chemical transformation. Initially the reactions sparked, thus dialysis (to remove 
salts) was carried out on all ligation reactions prior to electroporations using 2 day old 
electro-competent cells. All ligations were carried out with fragments previously obtained. 
This resulted in an efficiency of 10
5
 CFU/mL, a 10 fold increase to previous reactions. To 
increase the yield of fragments used for the ligation, digested fragments were isolated with 
agarase instead of spin columns following gel extractions. Reactions were run on a 0.7 % low 
melting agarose gel, the desired sizes were cut out and agarase was used to purify the 
fragments. The resulting concentrations of fragments were much higher than the spin column. 
A ligation was again attempted. This was also unsuccessful. A few more attempts were made 
to obtain fragments using low melting gels and ligation reactions as previously described, 
with no improvement in the result. 
Following these unsuccessful attempts, the library construction was carried out in Dr Adrie 
Steyn’s lab (K|RITH), by Ms Rukaya Asmal who spent 6 weeks at K|RITH to construct 
libraries. In this case, dilutions of restriction digests were set up as previously described; the 
appropriate reactions (i.e. in the correct fragment size range) were taken forward by sodium 
acetate precipitation of fragments, rather than gel extraction. pGADT7 was simultaneously 
cut with ClaI and followed by phosphatase treatment, sodium acetate precipitation and 
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phosphatase treatment for a second time just before use in ligation reactions. Ligation 
reactions were set up according to size differences between the vector and average size of 
insert. A 5.3× concentration difference was used and a reaction was set up using 300 ηg of 
vector and 60 ηg of insert. This reaction was left overnight, sodium acetate precipitated and 
resuspended in 5µL of 0.5 × TE buffer, of which 1µL was used in the electroporation reaction 
into Lucigen electrocompetent E. coli cells (Efficiency > 2 × 10
10
 CFU/mL). This yielded a 
transformation efficiency of 2.4 × 10
5 
CFU/mL. Further repeats yielded several libraries with 
efficiencies of 10
6
 CFU/ mL. A total of 11 separate libraries were made and pooled.  
From random libraries, 10 colonies were picked, miniprepped and digested using HinDIII to 
determine whether an insert/fragment was present. 
 
Figure 3.4. Agarose gel of HinDIII digestion of miniprepped clones. (A) HinDIII digestion of clones [Lanes 1, 
12] 1kb generuler; [Lanes 2, 4, 6, 8, 10, 13, 15, 17, 19, 21] uncut clones 1-10; [Lanes 3, 5, 7, 14, 16, 18, 20, 22] 
cut clones 1-10. (B) HinDIII digestion of pGADT7 compared to clones [Lane 1] 1kb generuler; [Lane 2] 
HinDIII digested pGADT7; [Lanes 3, 4] HinDIII digested clones 1 & 2. 
 
Digestion of parental pGADT7 with HinDIII will result in an 800 bp fragment. In those 
clones in the library with M. smegmatis genomic DNA fragments inserted into the vector, the 
800 bp fragment will increase in size, proportionately to the size of fragment inserted into the 
A B
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vector. Results of the digest demonstrated the presence of fragments of varying sizes, all 
bigger than the internal fragment. Figure 3.4B shows a comparison of pGADT7, without any 
insert, cut with HinDIII with that of some plasmids from the library, which contained bands 
that were larger. This analysis confirmed the presence of inserts in the library, which together 
with the number of clones recovered after transformation provided confirmation of a 
representative of coverage of the library of M. smegmatis (~10
6
). Freezer stocks of the 
libraries were made for use in yeast mating experiments.  
3.2. Cloning of DD-CPase-encoding genes into yeast bait vectors 
Genes were amplified using Phusion DNA polymerase. The initial PCR reactions contained a 
high amount of non-specific bands of varying intensities. Hence, a gradient PCR was carried 
out using an annealing gradient between 60 ºC – 70 ºC, the results of which are shown in 
Figure 3.5. 
 
Figure 3.5. Phusion Taq PCR of (A) dacB and (B) MSMEG_2433 using a temperature gradient. [Lane 1] 
Roche Marker II, [Lane 2] 60.0°C, [Lane 3] 60.7°C, [Lane 4] 61.9°C, [Lane 5] 63.7°C, [Lane 6] 66.0°C, 
[Lane 7] 68.0°C, [Lane 8] 69.2°C, [Lane 9] 70.0°C, [Lane 10] No template control, [Lane 11] Fwd primer 
only control, [Lane 12] Rev primer only control. 
 
All temperatures tested contained the band that corresponded to the correct size for both 
dacB, (1443 bp), and MSMEG_2433 (891 bp), Figure 3.5. However, the 70 ºC reaction was 
1   2   3   4   5   6   7   8   9   10  11  12 1   2   3   4   5   6   7   8    9    10   11  12A B
4361
4361
2322
2322
2027
2027
564
564
1443 bp
891 bp
58 
 
the cleanest, containing little to no non-specific bands and the resulting fragments were 
purified by PCR clean up. 
3.2.1. Transformation of DD-CPase genes into the yeast bait vector 
The bait vector (pGBKT7) was prepared in the same way as pGADT7. All purified products 
(from PCR) were of the correct sizes and contained no contamination by any other genes, 
Figure 3.6. The fragments were ligated and transformed and resulting transformants were 
screened for the correct insert band. One clone of each gene was then chosen and further 
analyzed by restriction mapping to confirm the genetic integrity of the clone, as demonstrated 
in Figures 3.7 and 3.8. 
 
Figure 3.6. Agarose gel of purified products of digested genes and pGBKT7 vector. [Lanes 1, 7] Roche Marker 
III [Lanes 2, 3] dacB, [Lanes 4-6] pGBKT7 restricted with NdeI and BamHI, [Lane 8] MSMEG_2433, [Lanes 
9-11] pGBKT7 restricted with NdeI and PstI. 
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Figure 3.7. Restriction profile of pGBKdacB. (A) Plasmid map of dacB cloned into yeast vector pGBKT7 (blue 
arrow). (B) Table showing the expected banding profiles of the restriction analysis of the pGBKdacB construct. 
(C) Agarose gel of restriction analysis of pGBKdacB [Lane 1] Ladder IV, [Lane 2] uncut pGBKT7, [Lane 3] 
EcoRV, [Lane 4] HinDIII, [Lane 5] NdeI + BamHI, [Lane 6] PvuI, [Lane 7] SphI. 
 
The fragments identified during restriction analyses of the clones were consistent with the 
expected banding patterns. Figures 3.7 and 3.8 shows the various enzymes used with the 
corresponding bands as expected. In 3.7C, the double digestion with NdeI and BamHI 
displayed extra bands, but this was attributed to the BamHI enzyme being contaminated and 
once the restriction was repeated with new BamHI, the extra bands disappeared (Appendix 
F). In Figure 3.8.C there is a single band missing for the HinDIII and NaeI digestions, which 
was attributed to a partial digest in the case of HinDIII. The HinDIII digestion was carried 
out previously to check the presence of insert though, and this produced the correct banding 
pattern (Appendix F). The selected clones were also sent for sequencing to Stellenbosch 
University (Central Analytical Facility – CAF), to further ensure that the genes have been 
cloned in-frame and there are no mutations from PCR amplification. Sequencing data 
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confirmed no mutations or deletions (data not shown) confirming the genetic integrity of the 
clones. 
 
Figure 3.8. Restriction profile of pGBK2433. (A) Plasmid map of MSMEG_2433 cloned into yeast vector 
pGBKT7 (blue arrow). (B) Table showing the expected banding profiles of the restriction analysis of the 
pGBK2433 construct. (C) Agarose gel of restriction analysis of pGBK2433 [Lane 1] Ladder IV, [Lane 2] uncut 
pGBKT7, [Lane 3] EcoRV, [Lane 4] HinDIII, [Lane 5] PstI, [Lane 6] NdeI + PstI, [Lane 7] PvuI, [Lane 8] 
NaeI. 
 
These clones were then transformed into the yeast strain Y187 as described in section 
2.11.2.1 and were taken forward into the yeast system. 
3.3. Yeast 2-Hybrid Interactions 
3.3.1. Transformation of library into AH109 yeast cells  
The library of the multiple electroporations prepared from E. coli was combined and sodium 
acetate precipitated prior to transformation into the yeast AH109 strain. Initially, a large scale 
transformation was carried out using 15 µg of the library DNA, which produced an efficiency 
of 10
3
-10
4
 CFU/mL. This was then up-scaled to a library scale transformation using 0.3 mg 
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of the library DNA, resulting in an efficiency of 10
6
 CFU/mL. This was taken forward into 
the yeast mating reaction.  
3.3.2. DD-CPase autonomous activation 
Detection of positive interactions using the Clontech Yeast Two-Hybrid system, which was 
employed in this study, involved an assessment of growth on various dropout supplemented 
media that lacked leucine/tryptophan/histidine and adenine, in various combinations. In this 
system, autonomous activation of the histidine reporter by vectors carrying protein fusions 
either with the activation or DNA binding domain can lead to the identification of false 
positive interactions. To prevent this, an inhibitor of autonomous histidine activation, 3-
Amino-1,2,4-triazole (3-AT), was added to the plates to reduce the chances of identifying 
false positive clones. To determine if autonomous histidine activation would occur in our 
screen, bait vectors were transformed with an empty prey vector and plated on histidine 
dropout media.  
If growth occurs, autonomous activation of the histidine reporter is taking place and the 
addition of 3-AT is required. For library screening, the concentration of 3-AT to be added 
was determined by plating yeast strains containing the bait vector only on increasing 
concentrations of 3-AT to achieve a concentration of 3-AT that gives no growth on histidine 
with a bait + empty prey vector carrying stain. Hence, vectors carrying bait DD-CPase genes 
were tested for autonomous activation as described in 2.11.2.2. The pGADT7 vector carries a 
leucine marker, while the pGBKT7 vector carries a tryptophan marker – these serve as 
selectable markers for the plasmids. Hence the strains were initially plated on the lowest 
stringency plates, i.e. lacking one amino acid, in order to select for either pGADT7 (SD/-Leu) 
or pGBKT7 (SD/-Trp). Thereafter, plating was carried out on higher stringency plates, i.e. 
lacking two amino acids (SD/-Leu/-Trp) in order to select for clones containing both vectors. 
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Table 3.1. Growth on SD plates lacking specific amino acids 
 SD/-Leu   SD/-Trp SD/-Leu/-Trp 
pGADT7 only + - - 
pGBKdacB only - + - 
pGBKdacB + pGADT7  +  + + 
pGBK2433 only - + - 
pGBK2433 + pGADT7 + + + 
+ = growth, - = no growth 
Results, shown in Table 3.1, revealed that the pGADT7 control only grew on SD/-Leu, while 
the controls containing no pGADT7 grew only on SD/-Trp. This was expected as these 
vectors can only grow in the absence of Leu for pGADT7, and Trp for pGBKT7. 
Transformants containing both vectors would grow on both these plates as both markers 
would be present, but only vectors which carry interacting partners would grow on higher 
stringency – Leu/Trp/His and Leu/Trp/His/Ade media. Two colonies of each of the bait – 
empty vector combinations on the SD/-Leu/-Trp were picked and plated as described in 
section 2.11.2.2.  
 
Figure 3.9. Spotting of DD-CPase transformants testing for autoactivation. (A) Serial dilutions of pGBK2433 + 
pGADT7 and pGBKdacB + pGADT7 on SD/-Leu/-Trp. (B) Serial dilutions of pGBK2433 + pGADT7 and 
pGBKdacB + pGADT7 on SD/-Leu/-Trp/-His with no (0 mM) 3AT. 
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Results showed growth on SD/-Leu/-Trp plates and no growth on SD/-Leu/-Trp/-His plates, 
Figure 3.9. Hence, autonomous activation of the His marker was not occurring with either of 
the clones and 3AT supplementation was not required for our screen. 
3.3.3. Yeast Mating 
Mating was carried out according to the manufacturer’s protocol for the Matchmaker™ Gold 
Yeast 2-Hybrid system. Cells were counted using a hemocytometer. Bait was used at a cell 
density of approximately 2×10
8
 CFU and prey (library) at approximately 3×10
7
 CFU. Zygote 
formation was checked using 40 × magnification on the light microscope (Appendix D). 
Initial mating efficiencies were approximately 0.5 %. The optimum efficiency according to 
the Matchmaker Gold Yeast Two Hybrid System User Manual, 2012, was 5 %. After 
numerous attempts and trouble shooting, mating efficiencies increased to 1 % (calculations in 
Appendix D), these conditions were used for screening. Once plated, a total of 100 and 160 
putative interacting colonies were identified for dacB and MSMEG_2433, respectively, on 
SD/-Leu/-Trp/-His/-Ade. These were picked and replica plated in order to rule out false 
positives, shown in Figure 3.10. 
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Figure 3.10. Mating clones. (A) Control reactions plated on SD/-Leu/-Trp. (B) dacB mating clones plated on 
SD/-Leu/-Trp/-His/-Ade. (C) MSMEG_2433 mating clones plated on SD/-Leu/-Trp/-His/-Ade. 
dacB Control 2433 ControlA
dacB potential positive Mating clonesB
MSMEG_2433 potential positive Mating clonesC
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X-α-Gal is included as a further indication of possible positive interactions. It works as a 
chromogenic substrate for α-galactosidase produced by some yeast strains and encoded by 
the mel1 gene in S. cerevisiae (Aho et al., 1997)  Colonies which were blue on SD/-Leu/-
Trp/-His/X-α-Gal and displayed growth on SD/-Leu/-Trp/-His/-Ade, shown in Figure 3.10, 
were then picked, the cell density adjusted to OD600 = 1 and 10 ul spotted on plates to 
reconfirm the result. The controls, the bait only, contained no colonies, Figure 3.10.A. 
 
Figure 3.11. Potential positive mating clones. (A) dacB mating clones plated on SD/-Leu/-Trp/-His/-Ade/X-α-
Gal. (B) MSMEG_2433 mating clones plated on SD/-Leu/-Trp/-His/-Ade/X-α-Gal. 
 
The results of this analysis revealed that 10 of the putative clones for dacB grew and 
remained blue, Figure 3.11A, and 24 of the putative clones for MSMEG_2433 remained blue, 
Figure 3.11B. The above-mentioned clones were taken forward by streaking each to single 
colonies and a blue colony of each was propagated, the plasmid isolated and the insert 
sequenced to determine the identity of the interacting partner.  
3.3.4. DacB and MSMEG_2433 have a number of possible interacting partners 
Plasmid isolation from yeast was carried out using the Zyppy™ miniprep kit which produced 
pure preparations for sequencing (data not shown). A few clones were subsequently digested 
A
B
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with HinDIII prior to sending for sequencing to ensure the presence of the insert. The digests 
are shown in Figure 3.12. 
 
Figure 3.12. Agarose gel of Zyppy plasmid miniprep and HinDIII digestion. [Lane 1] Roche marker III, [Lane 
2] miniprepped dacB_29, [Lane 3] HinDIII digested dacB_29, [Lane 4] miniprepped dacB_54, [Lane 5] 
HinDIII digested dacB_54, [Lane 6] miniprepped dacB_38, [Lane 7] HinDIII digested dacB_38 , [Lane 8] 
miniprepped 2433_127, [Lane 9] HinDIII digested 2433_127, [Lane 10] miniprepped 2433_116, [Lane 11] 
HinDIII digested 2433_116, [Lane 12] miniprepped 2433_135, [Lane 13] HinDIII digested 2433_135, [Lane 
14] miniprepped 2433_115, [Lane 15] HinDIII digested 2433_115. 
 
HinDIII digestion confirmed the presence of varying sizes of insert fragments as shown in 
Figure 3.12, which was quite promising in terms of finding interacting proteins. All the 
clones selected for plasmid isolation were sent for sequencing using primers specific for the 
T7 promoter and terminator sequences.  
Table 3.2. Sequencing results of potential positive mating clones using Blastx 
Clone Blastx Hits (mc
2
155) Putative conserved Domain 
 
DacB_29 
 
F0F1 ATP synthase subunit delta 
PRK13428 
 
 
DacB_26 Acyltransferase  
DacB_38 Acyltransferase Acyl_WS_DGAT 
 
DacB_83 Acyltransferase None identified 
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DacB_54 hypothetical protein MSMEG_0738 None identified 
DacB_88 hypothetical protein MSMEG_0738 None identified 
DacB_36 Transcriptional regulator, TetR 
family protein 
None identified 
 
DacB_38 
 
NADH dehydrogenase 
Ndh 
 
2433_19 
 
Chain A (single-stranded binding) 
 
 
2433_44 
bifunctional membrane-associated 
penicillin-binding protein 1A/1B 
ponA2 : penicillin-insensitive 
transglycosylase + penicillin-
sensitive transpeptidase 
 
None identified 
2433_81  
Hypothetical protein MSMEG_6786 
RibD_C 
 
 
 
2433_96 
HAD-superfamily hydrolase 
subfamily IA, variant 3:Beta-
phosphoglucomutase hydrolase 
PRK 
 
 
 
2433_97 
 
Integral membrane protein 
PiuB 
 
 
2433_103 GntR family transcriptional regulator None identified 
2433_107 beta-lactamase None identified 
 
2433_115 
 
NADH dehydrogenase 
Ndh 
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2433_116 
 
Chain A (single-stranded binding) 
 
 
 
 
2433_117 
 
acyl-CoA dehydrogenase 
ACAD Superfamily 
 
 
2433_127  
hypothetical protein MSMEG_2940 
Transcriptional Regulator 
 
 
2433_129  
Transcriptional regulator 
TetR 
 
 
 
2433_130 
bifunctional membrane-associated 
penicillin-binding protein 1A/1B 
ponA2 : penicillin-insensitive 
transglycosylase + penicillin-
sensitive transpeptidase 
 
None identified 
2433_135 Ribonucleotide-diphosphate 
reductase subunit alpha 
 
 
2433_136  
acyl-CoA dehydrogenase 
ACAD Superfamily 
 
 
2433_147 
 
UvrD/REP helicase 
addA_alphas 
 
 
The resulting sequencing data was analyzed using NCBI BLASTn to obtain the 
mycobacterial specific sequences, which were then run through NCBI BLASTx to determine 
the corresponding protein in order to identify the putative interacting proteins. The hits shown 
in Table 3.2 are those which produced 100 % identity in BLASTx. DacB was shown to 
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potentially interact with an acyltransferase and both DacB and MSMEG_2433 seem to 
interact with a common Tet regulator, which points to the possibility that both genes are 
under coordinated regulation. The acyltransferase could point to a DacB playing a more 
direct role in cross linking of the PG.  
MSMEG_2433-interacting proteins include a number of proteins involved in DNA 
replication such as helicases and ss-DNA binding proteins. This could point to a role for 
MSMEG_2433 in co-ordinating initiation of DNA replication and cell division. The most 
interesting hit was a PBP, specifically PonA2, which could point to the formation of a 
complex as PBP1 (PonA1) has been demonstrated to interact with and antagonistically affect 
the synergistic RpfB and RipA interaction (Hett et al, 2008; Hett et al, 2010). The most 
promising hits were then taken forward for further confirmation.  
3.3.5. Confirmation of interaction in putative clones isolated from yeast mating 
Confirmation was carried out as described in section 2.11.7. Initially, confirmation was 
carried on all potential positive interactions but due to the increased workload of multiple 
plating, we decided to focus on the PBP1A/1B hit only for further confirmation, since this 
protein is a PG synthetic protein. Confirmation studies in this case revealed reduced growth 
in low, as well as high stringency plates. Very few colonies were obtained from numerous 
experiments, Figure 3.13. This did not improve and precluded further confirmation of the 
PonA2 hit. Other putative interacting partners identified in this study await further 
confirmation.  
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Figure 3.13. Plates of confirmation reaction of clone 2433_130. (A) 2433_130 + pGBKT7::MSMEG2433 
plated on SD/-Leu/-Trp, (B) 2433_130 + pGBKT7::MSMEG2433 plated on SD/-Leu/-Trp/-His, (C) 2433_130 
+ pGBKT7 (empty) plated on SD/-Leu/-Trp. 
3.4. Localization of DacB 
3.4.1. Cloning of DacB-fluorescent protein fusions using crossover PCR  
The crossover (or stitch) PCR strategy that was initially used to obtain a fusion of the DD-
CPase gene/s (dacB in this case) to the fluorescent proteins is shown in Figure 3.14. The 
product of this reaction, would subsequently be cloned into pSE100 and localization patterns 
determined by microscopy. Stitch PCR of dacB with the 3 fluorescent genes was attempted. 
The first step, amplification of the dacB gene using PCR, resulted in single, clear bands of the 
desirable size (data not shown) which were purified for use as the mega-primer in the second 
step of the stitch PCR. However, during the second step, fusion of dacB and fluorescent gene, 
proved to be problematic. A number of optimization steps were attempted with no success 
and thus it was decided to try an alternative method.  
A B
C
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Figure 3.14. Stitch PCR strategy (DacB and GFP). Initially DacB is amplified with the incorporation of a 
restriction site in the forward primer and the reverse primer containing sequence that is homologous to the first 
˜18bp of the GFP gene. This product is then used as a “primer” with another reverse primer and the gene 
encoding a fluorescent protein as a template (another restriction site is introduced at the C terminus of the GFP). 
This results in a C-terminal fusion of the DacB to the GFP. Restriction sites are required for subsequent cloning 
steps 
 
3.4.2. 3-way cloning   
This method involved amplifying the DD-CPase gene and fluorescent gene separately and 
thereafter using a 3 way ligation to clone these genes into the desired vector, in this case 
pSE100. 
 3.4.2.1. DacB-mCherry 
Using this approach, the dacB and mCherry genes were successfully amplified (1458 bp for 
dacB and 720 bp for mCherry), Figure 3.15. Ligation reactions into pSE100 were successful 
and 24 test colonies were picked, miniprepped, and double digested using PacI and PstI to 
check for the presence of the correct insert (dacB + mCherry). All clones except one were 
positive (data not shown) and a single clone was then selected and further analysed by 
extensive restriction mapping, Figure 3.16. 
RE
Cloning RE + Fwd 
Primer
DacB
DacB
DacB GFP
Rev primer: homologous to first 
18 bp of fluorescent protein 
Cloning RE
RE
RE
First product – use as a template in the 
next PCR, with Fluorescent protein 
template and reverse primer 
Final, stitched product 
~18bp FP
Fluorescent protein
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Figure 3.15. Agarose gel of Phusion PCR of dacB and mCherry. [Lane 1] Roche Marker III, [Lane 2] dacB 
PCR, [Lane 3] No dacB forward primer control [Lane 4] No dacB reverse primer control, [Lane 5] No DNA 
control (dacB), [Lane 6] No DNA control (mCherry), [Lane 7] mCherry PCR, [Lane 8] No mCherry forward 
primer control, [Lane 9] No mCherry reverse primer control. 
 
Figure 3.16. Restriction profile of dacB and mCherry cloned into pSE100. (A) Plasmid map of dacB and 
mCherry cloned into pSE100 (blue arrow). (B) Agarose gel of restriction analysis of pSEdacB-mCherry [Lane 
1] Roche Marker IV, [Lane 2] uncut pSEdacB-mCherry, [Lane 3] PacI + PstI, [Lane 4] PvuI, [Lane 5] 
EcoRV, [Lane 6] BglII, [Lane 7] EcoRI. (C) Table showing the expected banding profiles of the restriction 
analysis of the pSEdacB-mCherry construct. 
 
1                      2        3            4         5               6         7            8           9
21226
5148
1584
1375
947
831
4268
3530
2027
564
1904
1458 bp
720 bp
dacB mCherry
test
test
Controls Controls
1            2           3            4          5           6             7       
Lane Length (bp)
1 Marker IV
2 Uncut clone
3 PacI + PstI 5513, 2126
4 PvuI 4460, 1826, 921, 432
5 EcoRV 7639
6 BglII 7639
7 SacI 3166, 1471, 1458, 
1019, 525
8 EcoRI 3795, 2306, 1538
5513 bp
2126 bp
4460 bp
1826 bp
921 bp
432 bp
7639 bp
3795 bp
2306 bp
1538 bp
pSE100 + dacB + mCherry
7639 bps
1000
2000
3000
4000
5000
6000
7000
Pac I 378
Pvu I 426
Pvu I 1347
Pvu I 1779
Pst I 2513
EcoRI 2519
EcoRV 2525
Pvu I 3605
Bgl II 3819
RI 4057Eco
RI 6363Eco
rrnBT2
UV15tetO
dacB + mCherry
T4g32
ori myc
hygR
ColE1
A
B
C
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Restriction mapping analysis of pSEdacB-mCherry, revealed the presence of the correct 
expected patterns for all enzymes tested, Figure 3.16B. The clone was then sequenced to 
confirm that PCR amplification did not introduce mutations. Sequence analysis revealed no 
mutations or deletions and confirmed the fusion junction between dacB and mCherry (data 
not shown). Following mapping, clones were electropolated into M. smegmatis, a single 
colony was picked from each test plate, DNA was extracted as per section 2.2.1.2, followed 
by PCR using dacB forward primer and mCherry reverse primer to ensure the cell contains 
the vector with the insert. PCR resulted in the expected band of 2126 bp (Appendix E). This 
clone was taken forward to determine localization pattern of DacB by microscopy. 
 
Figure 3.17. Confocal microscopy of pSEdacB-mCherry construct. (A) and (B) pSEdacB-mCherry construct. 
[1] DIC, [2] mCherry, [3] Merged channels. Blue arrows indicate diffused localization. Scale bar: 5µm for all 
images. 
 
Fluorescence microscopy to detect mCherry, with Differential Interference Contrast (DIC) to 
identify cells, revealed dispersed localization of the DacB-mCherry fusion, without any 
specific localization patterns, Figure 3.17. Analyses with different preparation of cells yielded 
the same result. The lack of any observable localization patterns may be due to folding 
problems with the fusion protein (Stiel et al., 2008, Lukyanov et al., 2005). Analysis using 
B
1 2
3
12
3
A
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the SignalP algorithm indicates that DacB has a signal sequence (Ealand and Kana, 
unpublished) suggesting that it is transported to the periplasmic compartment. In this case, 
the folding and processing of the fusion protein in the periplasm may be affected, leading to 
diffused localization. To further study DacB localization in mycobacteria, we decided to 
change the fluorescent protein tag on DacB and opted to use the Venus fluorescent protein. 
3.4.2.2. DacB-Venus 
A fusion of DacB to the Venus fluorescent protein was obtained by three-way cloning of the 
genes generated through PCR. PCR amplification of the desired genes was successful, as 
indicated by presence of the expected band sizes of ~1458 bp for dacB and ~710 bp for 
Venus, Figure 3.18. The controls, including the no DNA controls, were clean and indicated 
no cross-contamination. The non-specific bands in the forward primer and reverse primer 
controls in Figure 3.18A were of a much lower intensity than the specific band and were 
attributed to by-products of mis-priming on wild type genomic DNA. Following three-way 
ligation, 10 putative colonies were digested with PacI + HinDIII to assess the presence the 
insert. One positive clone was selected and analysed by extensive restriction mapping, Figure 
3.19. 
 
Figure 3.18. Agarose gels of Phusion PCR of dacB and Venus. (A) dacB phusion PCR [Lane 1] dacB PCR,  
[Lane 2] No dacB forward primer control, [Lane 3] No dacB reverse primer control, [Lane 4] No DNA control 
(dacB), [Lane 5] Roche marker IV. (B) Venus phusion PCR [Lane 1] Roche marker IV, [Lane 2] Venus PCR, 
[Lane 3] No Venus forward primer control [Lane 4] No Venus reverse primer control, [Lane 5] No DNA 
control (Venus). 
1         2          3           4           5   
710 bp
1   2       3        4               5
1458 bp
A B
dacB
Venus
Controls Controlstest
test
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Figure 3.19. Restriction profile of dacB and Venus cloned into pSE100. (A) Plasmid map of dacB and Venus 
cloned into pSE100 (blue arrow). (B) Agarose gel of restriction analysis of pSEdacB-Venus [Lane 1] Roche 
Marker IV, [Lane 2] uncut pSEdacB-Venus, [Lane 3] PacI + HinDIII, [Lane 4] BglII, [Lane 5] BamHI, [Lane 
6] EcoRI, [Lane 7] HinDIII. (C) Table showing the expected banding profiles of the restriction analysis of the 
pSEdacB-Venus construct. 
 
Restriction analysis of the putative clone revealed the correct banding patterns for all 
enzymes tested, as shown in Figure 3.19B. This is indicative of the genes being cloned in the 
correct orientation, in-frame, a result that was confirmed by sequencing, which revealed no 
mutations or deletions (data not shown). Following mapping, the plasmid was electroplated 
into M. smegmatis and PCR was carried out using dacB forward primer and Venus reverse 
primer to ensure the cell contains the vector with the insert. PCR showed a sharp band of the 
correct size (2172 bp) (Appendix E). Freezer stocks were made of M. smegmatis clones and 
microscopy was then carried out. 
Lane Length (bp)
1 Marker IV
2 Uncut clone
3 PacI+ HinDIII 5490, 2173
4 BglII 5646, 2017
5 BamHI 7663
6 EcoRI 5357, 2306
7 HinDIII 7663
1           2          3           4            5           6           7       
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2173 bp
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7663 bp
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1000
2000
30004000
5000
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7000
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Bgl II 1274
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I 3755Nco
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UV15tetO
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T4g32
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ColE1
A
B
C
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Figure 3.20. Fluorescent microscopy of pSEdacB-Venus construct. (A) and (B) pSEdacB-Venus construct. [1] 
DIC, [2] Fluorescence, [3] Merge. Red arrow indicates longer cells, White arrows indicate polar and septal 
localizations and variations thereof. Dotted arrows lead to zoomed image. Scale bar: 5 µm for (A) and (B), 2 µm 
for zoomed images. 
 
The results of confocal microscopy to detect the DacB-Venus fusion protein is shown in 
Figure 3.20. The majority of DacB detected seemed to have dispersed localization along the 
entire cell. However, there was a minority of the fusion protein that was found in punctate 
localization either at the pole or along the lateral axis of the cell, Figure 3.20. In some cases, 
localization of DacB at the septum was also observed. With regards to polar localization, we 
noted a significant proportion of monopolar, as well as monopolar plus septal localization, 
with lower occurrences of bipolar, septal only and bipolar with septal localization, Figure 
3.20. Venus, with range of 510 – 530 nm, is characterized as a yellow fluorescent protein 
(YFP) and has the disadvantage of having very low photostability, i.e. it bleaches at a rapid 
rate. It is approximately 75 % less photostable than other YFPs and thus very few images can 
1 2 3
B
A
1 2 3
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be captured before bleaching occurs (Shaner et al., 2005). This could explain why initially 
localization patterns were observed (such as a high occurrence of polar localization), but 
thereafter, only diffused localization was observable. After numerous attempts, the signal 
from the DacB-Venus fusion protein could not be improved and it was opted to search for a 
more stable fluorescent protein. In this regard, our collaborator, Dr Musa Mhalanga provided 
us with a photo-switchable GFP - rsEGFP. 
3.4.2.3. DacB-rsEGFP 
The fusion of DacB to rsEGFP was done through three-way cloning. PCR amplification of 
the dacB gene yielded a fragment of the correct size, but with a number of non-specific 
bands. Due to the high concentration of the desired band present, Figure 3.21A, it was 
possible to gel extract the dacB gene. PCR for the rsEGFP yielded the desired band and the 
no DNA controls in both cases were clean, Figure 3.21. Double digests and 3 way ligations 
were carried out as previously described. Twelve colonies were picked and screened by 
double digestion using HinDIII and BamHI to check for the presence of the insert (dacB and 
rsEGFP). All colonies were positive clones, with the expected bands of 5508 bp and 2172 bp 
(data not shown). One clone was then taken forward and analysed by restriction digest, 
Figure 3.22. 
 
Figure 3.21. Agarose gels of Phusion PCR of dacB and rsEGFP. (A) dacB phusion PCR [Lane 1] Roche 
marker IV, [Lane 2] No dacB forward primer control, [Lane 3] No dacB reverse primer control, [Lane 4] No 
DNA control (dacB), [Lane 5] dacB PCR. (B) rsEGFP phusion PCR [Lane 1] Roche marker IV, [Lane 2] 
rsEGFP PCR, [Lane 3] No rsEGFP forward primer control [Lane 4] No rsEGFP reverse primer control, [Lane 
5] No DNA control (rsEGFP). 
1              2              3               4               5   1              2              3               4               5   
1458 bp
720 bp
A B
dacB rsEGFP
Controls test Controlstest
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Figure 3.22. Restriction profile of dacB and rsEGFP cloned into pSE100. (A) Plasmid map of dacB and rsEGFP 
cloned into pSE100 (blue arrow). (B) Agarose gel of restriction analysis of pSEdacB-rsEGFP [Lane 1] Roche 
Marker IV, [Lane 2] uncut pSEdacB-rsEGFP, [Lane 3] HinDIII + BamHI, [Lane 4] EcoRI, [Lane 5] BglII, 
[Lane 6] BamHI, [Lane 7] PacI, [Lane 8] PvuI. (C) Table showing the expected banding profiles of the 
restriction analysis of the pSEdacB-rsEGFP construct. 
 
Restriction analysis of the pSEdacB-rsEGFP construct was indicative of in-frame cloning of 
the genes since the restriction profiles were all correct, Figure 3.22B. The EcoRI restriction 
seemed to produce two bands instead of three, but this was attributed to the 2306 bp and 2251 
bp being of similar size, such that they appear as one band of bright intensity. Sequencing of 
this construct revealed no mutations or deletions and confirmed in-frame cloning. 
Electroporation into M. smegmatis was carried out, followed by PCR using dacB forward 
primer and rsEGFP reverse primer as confirmation for the presence of the correct vector. 
PCR showed a sharp band of 2172 bp, which was the expected size (data not shown). 
Microscopy of this strain was carried out simultaneously with the strain including the 
tetracycline repressor to allow for regulation of expression for the fusion protein. TEM using 
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the immunogold strategy was also carried out on the strain, which lacked the tetracycline 
repressor and is expected to over-express the DacB-rsEGFP fusion protein. Immunogold is an 
antibody based strategy which utilizes rabbit anti-EGFP and gold-labeled goat anti-rabbit as 
the primary and secondary antibodies, with the primary antibody recognizing GFP/EGFP 
epitope, and the secondary antibody recognizing the complex of the primary antibody and the 
epitope, resulting in the ability to view the gold nanoparticles as black spots on TEM, Figure 
3.23 (Hainfeld et al., 1991).  
 
Figure 3.23. Immunogold strategy. The primary antibody with the antigen (eGFP epitope), is recognised by the 
secondary antibody to which gold nanoparticles are attached. This results in aggregation of the gold particles, 
which is viewed as black dots during TEM. Adapted from (Hwang et al., 2008) 
+
1ᴼ AB: rabbit 
anti eGFP AB
Gold 
Nanoparticle
2° AB: gold-
labeled goat 
anti-rabbit AB
Antigen
Immunogold strategy
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Figure 3.24. TEM of pSEdacB-rseGFP construct using Immunogold. (A) Negative control (No 1º AB), (B) 
Construct- 1:100 dilution of 1º AB, (C) Construct- 1:500 dilution of 1º AB. Scale bar: 0.2 µm. Black dots 
indicate positive immunogold localization. 
 
The results of the Immunogold method using an antibody directed to the GFP is shown in 
Figure 3.24, which revealed that DacB localized along the entire cell wall, however in some 
cells, protein seemed to concentrate at one pole. Due to the way cells were prepared for TEM, 
i.e. through embedding in resin, the cells get cut in varying planes either along the lateral axis 
of the cell or perpendicular to it (these are the cells that display a spherical morphology in 
Figure 3.24). Thus it is difficult to definitively comment on polarity at a specific site. The 
only pattern that can be concluded is that dacB is present along the entire cell wall and may 
concentrate at a single pole. The aberrant shapes observed were not due to the over-
expression of the gene, but as a result of the immunogold treatment. The structural integrity 
of the cells were affected when treated with lead citrate, thus any phenotypic changes due to 
over-expression would not be able to be observed using this methodology.  
 
A B C
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3.4.3. Growth kinetics and Repression of dacB  
The localization patterns of dacB were further analyzed by the addition of the tetracycline 
repressor (carried on vector pMC1s) in order to determine whether the localization pattern 
changes when the gene dosage is reduced. PCR was used to confirm pMC1s integration. The 
basic principle of this method relies on 2 sets of primers, with one set binding the tRNA
glycine
 
flanking locus on the genomic DNA and the other binding the plasmid integration site (AP 
site) flanking the plasmid DNA (Guo et al., 2007). Hence if amplification occurs, integration 
was successful and occurred at the correct site. This analysis was only carried out only with 
the DacB-rsEGFP fusion. The repressor was electroporated into the M. smegmatis clone 
already containing pSEdacB-rsEGFP. Confirmation was performed by PCR. 
 
Figure 3.25. PCR screen for integration of pMC1s. [Lane 1] Roche Marker IV, [Lane 2] attBS2, attL4 PCR, 
[Lane 3] attL2, attBS1 PCR. 
 
PCR analysis confirmed that pMC1s integrated in the correct position - at the attB site - since 
both sets of att primers amplified the correct amplicons, Figure 3.25. Expression of dacB 
could now theoretically be controlled by the addition of anhydrous tetracycline (AHT). With 
this method, the addition of AHT will increase gene expression. 
1       2      3    
421 320 bp
282 bp
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3.4.3.1. Altered levels of dacB has no effect on growth kinetics of M. smegmatis 
We hypothesized that introduction of the fusion DacB-rsEGFP protein may affect cell growth 
since over-expression of PG remodelling enzymes has been known to affect cell wall 
stability. To test for this, growth was determined by taking OD600nm readings at 6, 9 and 18 
hours after inoculation of the pSEdacB-rsEGFP with the repressor (pMC1s) construct 
alongside M. smegmatis mc
2
155 (as described in section 2.9.1.). All experiments were set up 
in triplicate to ensure results were consistent and unbiased. The growth curve did not show 
any significant differences in growth rates of the strains (data not shown).  
3.4.3.2. Regulated expression of the fusion protein.  
To determine if addition of AHT would result in an increase in gene expression of the dacB-
rsEGFP fusion, qPCR was carried out with the repressor and without against wild type M. 
smegmatis mc
2
155. 
 
Figure 3.26. Expression data of wild type M. smegmatis against the pSEdacB-rsEGFP construct with the 
pMC1s repressor. Data shown are representative of three independent experiments. 
 
As expected, gene expression in the repressor-less strain was higher than in the strain 
carrying the repressor, Figure 3.26. All strains were normalized against wild type and plotted. 
There were no significant differences in expression between the different concentrations of 
AHT inducer. Considering this, we hypothesized that the inability to control expression could 
be attributed to the pSE100 that was used as an episomal instead of integrative format, and 
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thus multiple copies of the gene (and the tetO operator) were present and the repressor cannot 
effectively control the expression of the dacB gene, i.e. it partially represses the gene, but not 
to the level required. Hence under all conditions tested, the DacB fusion protein was over-
expressed relative to wild type levels. Despite these limitations, microscopy was carried out 
at the following time points during a growth curve: (I) 6 hours post inoculation – 
corresponding to early log phase and (II) 18 hours post inoculation – corresponding to mid – 
log phage.  
3.4.3.3. Over-expression of DacB causes increased monopolar localization 
Confocal microscopy at early- and mid- log phase are shown in Figure 3.27 and Figure 3.28, 
with a graph quantifying the occurrence of the different patterns shown in Figure 3.29. The 
results showed that most strains contained increased monopolar localization, with the 
repressor-less strain containing the highest frequency of monopolar localization, Figures 
3.27B and C, 3.28B, 3.29. The addition of 50 ηg/mL AHT, in the strain containing the 
repressor, yielded similar percentages of localization between strains, with the highest 
percentage still being the monopolar localization. Cells with the repressor seemed to also 
have a higher percentage of monopolar localization, but also consistent (albeit lower) 
occurrences of the other patterns, Figures 3.27C-L, 3.28B-H and 3.29. At lower AHT 
concentrations, a very high number of cells contain dispersed localization, Figures 3.27C-F, 
3.28B and 3.28C. At 5 ηg/mL AHT, occurrence of dispersed localization seemed to decrease, 
Figures 3.27G, 3.27H and 3.28D, and at 50 ηg/mL and 100 ηg/mL, there was a higher 
occurrence of localization concentrated to specific locations of the cell compared to dispersed 
fluorescence, Figures 3.27I-L and 3.28E-H. The lack of any significant differences in 
localization patterns between strains with different levels of AHT inducer is consistent with 
the expression data viewed in Figure 3.26, where levels of gene expression are similar for 
these strains. 
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Figure 3.27. Confocal microscopy at early log phase. (A) and (B) pSEdacB-rseGFP (R-), (C) and (D) pSEdacB-
rsEGFP + pMC1s 0 AHT, (E) and (F) pSEdacB-rsEGFP + pMC1s 0.5 AHT, (G) and (H) pSEdacB-rsEGFP + 
pMC1s 5 AHT, (I) and (J) pSEdacB-rsEGFP + pMC1s 50 AHT, (K) and (L) pSEdacB-rsEGFP + pMC1s 100 
AHT. [1] DIC, [2] Fluorescence, [3] Merge. Blue arrows indicate punctate localization along the cell, White 
arrows indicate monopolar localization. Dotted arrows lead to zoomed image. Scales bars: 5 µm for (A) – (I) 
and (K), and 2 µm for zoomed images, (J) and (L). 
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Figure 3.28. Confocal microscopy during mid-log phase of growth. (A) pSEdacB-rsEGFP (R-), (B) pSEdacB-
rsEGFP + pMC1s 0 AHT, (C) pSEdacB-rseGFP + pMC1s 0.5 AHT, (D) pSEdacB-rsEGFP + pMC1s 5 AHT, 
(E) and (F) pSEdacB-rsEGFP + pMC1s 50 AHT, (G) and (H) pSEdacB-rsEGFP + pMC1s 100 AHT. [1] DIC, 
[2] Fluorescence, [3] Merge. Blue arrows indicate punctate localization along the cell, White arrows indicate 
monopolar localization. Dotted arrows lead to zoomed image. Scales bars: 5 µm for (A) – (E) and (G), and 2 µm 
for zoomed images, (F) and (H). 
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Cell localization patterns from all microscopy were quantified by counting each type of 
pattern viewed, results are shown in Fig. 3. 29. 
 
Figure 3.29. Graph of localization patterns observed during microscopy. (A) Localization patterns during early 
log-phase. (B) Localization patterns during mid-log phase.  
 
3.4.3.4. Cloning of dacB-rsEGFP into integrating vector pTweety 
A modified pTweety integrating vector with a gentamycin resistance cassette was created in 
our lab by Nicole C. Narrandes (unpublished) which was used to clone the dacB-rsEGFP 
gene (including the tetO). This vector was integrated at the Tweety site in the mycobacterial 
genome and the pMC1s vector was integrated at the attB site (Pham et al., 2007). We 
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hypothesized this strategy would reduce the gene dosage for the fusion protein and allow for 
better regulation of expression of the dacB gene. 
The cloning was carried out as described in section 2.6.2, where 20 potential clones were 
digested using XbaI. Two orientations of the insert were possible, with expected band sizes of 
8016bp and 2517bp or 10269bp and 264bp, respectively. All clones seemed to be in one 
orientation only (data not shown) and a single clone was chosen for further restriction 
analysis, Figure 3.30. 
 
Figure 3.30. Restriction profile of tetO-dacB-rsEGFP cloned into pTweety. (A) Plasmid map of tetO-dacB-
rsEGFP cloned into pTeety (blue arrow). (B) Agarose gel of restriction analysis of pTw::dacB-rsEGFP [Lane 1] 
Roche Marker IV, [Lane 2] uncut pTw::dacB-rsEGFP, [Lane 3] XbaI, [Lane 4] HinDIII, [Lane 5] EcoRI, 
[Lane 6] BamHI, [Lane 7] BglII, [Lane 8] PvuI. (C) Table showing the expected banding profiles of the 
restriction analysis of the pTw::dacB-rsEGFP construct. Circles indicate the position of the faint bands. 
 
Lane Enzyme Expected band/s
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3 XbaI 8016, 2517
4 HinDIII 10533
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All enzymes used to digest the plasmid yielded the expected banding patterns, Figure 3.30. 
This is indicative of the insert being cloned correctly into the pTweety vector. In order to 
control expression, the strain was transformed with pMC1s, as previously described. 
 
Figure 3.31. PCR screen for integration of pMC1s. [Lane 1] Roche Marker IV, [Lane 2] attBS2, attL4 PCR, 
[Lane 3] attL2, attBS1 PCR. 
 
PCR screen for the pMC1s repressor-encoding gene yielded the correct bands (screen 
explained in section 3.4.3), confirming that the repressor integrated at the correct site, Figure 
3.31. A PCR screen was also carried out on the repressor-less strain to determine the presence 
of dacB-rsEGFP, which produced the desired band of 2165 bp (data not shown).  
We then attempted to grow pTw::dacB-rsEGFP, lacking the repressor; however a poor 
biomass was obtained during log phase. Different approaches, including growing the strain in 
7H9 with OADC (Oleic acid-albumin-dextrose-catalase) instead of glycerol; growing at 30 
ºC instead of 37 ºC; shaking at a higher speed and growing in LB instead of 7H9 did not 
improve this. The strain was taken forward by growing in the selective media and thereafter 
in varying concentrations of AHT. There was notable variability in the biological replicates, 
which precluded expression analysis however, microscopy was still carried out. 
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Figure 3.32. Confocal microscopy of pTw::dacB-rsEGFP with pMC1s construct, at varying concentrations of 
AHT during log phase. (A) pTw::dacB-rseGFP + pMC1s 0 AHT, (B) pTw::dacB-rsEGFP + pMC1s 0.5 AHT, 
(C) pTw::dacB-rsEGFP + pMC1s 5 AHT, (D) and (E) pTw::dacB-rsEGFP + pMC1s 50 AHT, (F) and (G) 
pTw::dacB-rsEGFP + pMC1s 100 AHT. [1] DIC; [2] Fluorescence; [3] Merged. White arrows indicate 
monopolar and/or septal localization, Pink arrows indicate bipolar localization, and Purple arrows indicate 
bipolar and septal localization. Dotted arrows lead to zoomed image. Scales bars: 5 µm for (A) – (D) and (F), 
and 2 µm for zoomed images, (E) and (G). 
 
 Microscopy results revealed localization patterns at lower concentrations of AHT to be very 
similar to those observed previously, i.e. a high proportion of monopolar localization, Figure 
3.32A and 3.32B. However, supplementation with 5 ηg/mL AHT yielded increased bipolar 
and bipolar with septal localization, with monopolar staining still being the in the highest 
proportion, Figures 3.32C and 3.33. At 50 ηg/mL and 100 ηg/mL AHT, the bipolar and 
bipolar plus septal localization increased, with a decrease in monopolar localization, Figures 
3.32D-3.32G, 3.33. An interesting observation was that at the higher concentrations of AHT 
(50 ηg/mL and 100 ηg/mL), diffused localization seemed to decrease drastically, with an 
increase in the concentration of fluorescent accumulation at specific locations, Figures 
3.32D-3.32G, 3.33. This was consistent in all experiments carried out using AHT as 
described in the previous section. This could point to one of two scenarios, either higher AHT 
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concentrations aids in localization when using fluorescent tags or the AHT itself is affecting 
the fluorescent protein. It is difficult to determine which is occurring, and the mechanism 
could be related to the expression of the fusion protein. 
 
Figure 3. 33. Graph of localization patterns observed during microscopy of pTw::dacB-rsEGFP. 
 
Due to the above-mentioned difficulty of growing the strain under standard conditions, we 
decided to confirm that integration of the pTw::dacB-rsEGFP construct had occurred in a site 
specific manner. For this, Southern Blot analysis was carried out using the enzymes BclI and 
StuI with the dacB opening reading frame serving as the probe. The integration site of the 
pTweety vector is the tRNA
lys
 (MSMEG_4746).  
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Figure 3. 34. Southern Blot analysis of pTw::dacB-rsEGFP construct. (A) Genome map of mc
2
155 dacB region, 
(B) Genome map of integrated construct, (C) Southern blot of mc2155 and construct [Lane 1] BclI restriction of 
mc2155, [Lane 2] BclI restriction of pTw::dacB-rsEGFP construct, [Lane 3] BclI restriction of pTw::dacB-
rsEGFP construct with pMC1s, [Lane 4] StuI restriction of mc
2
155, [Lane 5] StuI restriction of pTw::dacB-
rsEGFP construct, [Lane 6] StuI restriction of pTw::dacB-rsEGFP construct with pMC1s. Blue arrows indicate 
required gene (dacB or dacB-rsEGFP), red arrows indicate genes flanking required gene (dacB or dacB-
rsEGFP) 
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Southern blot analysis yielded the correct, expected band sizes for mc
2
155, for both 
restriction enzymes used (4622 bp and 809 bp for BclI and 8446 bp for StuI). BclI digestion 
of mc
2
155 produces two bands due to the presence of a BclI site in the dacB gene, Figure 
3.34A and C. The pTw::dacB-rsEGFP construct contained both the wild type bands (4622 bp 
and 809 bp), as well as two other bands, of 6738 bp and 3768 bp, as expected, Figure 3.34B 
and C. StuI digest of pTw::dacB-rsEGFP also contained the wild type band (8446 bp), Figure 
3.34A and C, and one other band of 16893 bp, which was expected, Figure 3.34B and C. 
Both these results indicate that integration occurred at the correct site. Thus, the inability to 
grow this strain is not due to a defect in integration. Considering this, the growth defect may 
be attributed to the deregulated expression of DacB, which would explain the inability of the 
repressor-less strain to grow, and the very slow growth of the strain with the repressor. To 
circumvent this, the construct may need to be cloned into a different backbone - or the native 
dacB gene could be replaced by one carrying the rsEGFP fusion.  
3.5. Localization of MSMEG_2433 
3.5.1. MSMEG_2433-Venus 
Localization of MSMEG_2433 was carried out in a manner similar to DacB where the gene 
encoding this protein was fused to that encoding the Venus protein using cloning. PCR 
amplification of the genes was successful, Figure 3.35. The MSMEG_2433 no DNA control 
contained a faint band at 852 bp, this was repeated again and the band disappeared, indicating 
that this band was due to cross-contamination (data not shown). Products were ligated as 
previously described. And following transformation 12 colonies were selected and the DNA 
digested using PacI and HinDIII (data not shown). One positive clone was selected and 
mapped through restriction analysis. 
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Figure 3. 35. Agarose gels of Phusion PCR of MSMEG_2433 and Venus. [Lane 1] Roche marker IV, [Lane 2] 
MSMEG_2433 PCR, [Lane 3] No MSMEG_2433 forward primer control, [Lane 4] No MSMEG_2433 reverse 
primer control, [Lane 5] No DNA control (MSMEG_2433), [Lane 6] Roche marker IV, [Lane 7] Venus PCR, 
[Lane 8] No Venus forward primer control, [Lane 9] No Venus reverse primer control, [Lane 10] No DNA 
control (Venus). 
 
 
Figure 3. 36. Restriction profile of MSMEG_2433 and Venus cloned into pSE100. (A) Plasmid map of 
MSMEG_2433 and Venus cloned into pSE100 (blue arrow). (B) Agarose gel of restriction analysis of pSE2433 
-Venus [Lane 1] Roche Marker IV, [Lane 2] uncut pSE2433 -Venus, [Lane 3] PacI + HinDIII, [Lane 4] BglII, 
[Lane 5] EcoRI, [Lane 6] NcoI, [Lane 7] HinDIII. (C) Table showing the expected banding profiles of the 
restriction analysis of the pSE2433 -Venus construct. 
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The restriction profile of the pSE2433-Venus yielded the correct banding patterns for the 
enzymes tested, Figure 3.36. - indicating that the cloning was successful. Sequencing further 
confirmed this and revealed no mutations or deletions. Following electroporation into M. 
smegmatis, PCR was carried out using the MSMEG_2433 forward primer and Venus reverse 
primer, which resulted in a clear band at 1607 bp, as expected (data not shown). Confocal 
microscopy was carried out in order to determine the localization patterns of this protein, 
Figure 3.37.  
 
Figure 3. 37. Fluorescence microscopy of pSE2433-Venus. [1] DIC; [2] Fluorescence; [3] Merged. White 
arrows indicate polar or septal localization. Dotted arrows lead to zoomed image. Scale bar: 5µm, 2 µm for 
zoomed images. 
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Figure 3. 38. TEM of Immunogold pSE2433-rsEGFP construct. (A) Negative control (No 1º AB), (B) 
Construct- 1:100 dilution of 1º AB, (C) Construct- 1:500 dilution of 1º AB. Scale bar: 0.2 µm. 
 
MSMEG_2433 is constituently over-expressed and would be expected to localize at sites of 
new peptidoglycan incorporation due to the action of DD-CPase genes in general. However, 
most cells indicated dispersed localization, with a small percentage of cells showing 
monopolar or septal localization, Figure 3.37, white arrows. In addition to confocal 
microscopy, TEM was carried out using the Immunogold strategy, Figure 3.38, which 
showed MSMEG_2433 to be localized/dispersed along the cell wall. 
3.5.2 MSMEG_2433-rsEGFP 
Construction of an MSMEG_2433-rsEGFP fusion required PCR amplification and three-way 
cloning. In this case, PCR amplification, yielded fragments of the correct size indicated by 
the bands of 852 bp and 721 bp, Figure 3.39. The faint band present in the no DNA control 
was again due to cross-contamination, as the PCR reactions for the Venus construct and the 
rsEGFP construct were carried out at the same time. Following ligation, 12 putative clones 
were digested using PstI and HinDIII. Only one clone produced the expected banding pattern 
of 5508bp and 2172bp (data not shown), which was then mapped further. 
A B C
101 
 
 
Figure 3. 39. Agarose gels of Phusion PCR of MSMEG_2433 and rsEGFP. [Lane 1] Roche marker IV, [Lane 
2] MSMEG_2433  PCR, [Lane 3] No MSMEG_2433  forward primer control, [Lane 4] No MSMEG_2433 
reverse primer control, [Lane 5] No DNA control (MSMEG_2433), [Lane 6] Roche marker IV, [Lane 7] 
rsEGFP PCR, [Lane 8] No rsEGFP forward primer control [Lane 9] No rsEGFP reverse primer control, [Lane 
10] No DNA control (rsEGFP). 
 
Figure 3. 40. Restriction profile of MSMEG_2433 and rsEGFP cloned into pSE100. (A) Plasmid map of 
MSMEG_2433 and rsEGFP cloned into pSE100 (blue arrow). (B) Agarose gel of restriction analysis of 
pSE2433-rsEGFP [Lane 1] Roche Marker IV, [Lane 2] uncut pSE2433-rsEGFP, [Lane 3] PstI + HinDIII, 
[Lane 4] EcoRI, [Lane 5] NcoI, [Lane 6] HinDIII, [Lane 7] PvuI. (C) Table showing the expected banding 
profiles of the restriction analysis of the pSE2433-rsEGFP construct. 
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The restriction profile of the pSE2433-rsEGFP vector yielded the correct sizes for the 
enzymes tested, Figure 3.40. An extra band was observed for the PvuI digest which was 
attributed to partial digestion. Following electroporation into M. smegmatis, PCR using the 
MSMEG_2433 forward primer and rsEGFP reverse primer was carried out, which resulted in 
a sharp band at 1616 bp, as expected (Appendix E). Confocal microscopy was carried out, 
Figure 3.41. 
 
Figure 3. 41. Fluorescence microscopy of pSE2433-rsEGFP constructs. [1] DIC; [2] Fluorescence; [3] Merged. 
White arrows indicate polar or septal localization. Dotted arrows lead to zoomed image. Scale bar: 5µm, 2 µm 
for zoomed images. 
 
Microscopy of pSE2433-rsEGFP resulted in similar patterns as the Venus microscopy, i.e. 
majority dispersed localization with a small percentage of monopolar or septal localization, 
Figure 3.41. No quantification or further analysis could be carried out.   
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3.6. Single DD-CPase gene knock outs (KOs) have no effect on antibiotic susceptibility 
This component of this MSc study was aimed at further analyzing DD-CPase function. For 
this, antibiotic susceptibility of mutants lacking individual DD-CPase encoding genes was 
tested by MICs, as described in section 2.8. Single deletion mutants were obtained from Dr 
C. Ealand, who had previously carried out phenotypic characterisation on these strains. The 
data is shown in Table 3.3. Antibiotics were chosen based on ability to damage the cell wall 
as well as a few general TB drugs to determine any changes in permeability. This approach 
was aimed at trying to extrapolate function of the individual genes by antibiotic 
susceptibility, and thereby assessing any specific phenotypic differences resulting from the 
loss of DD-CPase-encoding genes. Neither determination of MICs using broth, Table 3.3, nor 
plating on solid media with antibiotics of varying concentrations (data not shown) revealed 
any differences in antibiotic susceptibilities. Most antibiotics tested in liquid culture resulted 
in a 2-fold variation between experiments, with the exception of Erythromycin and Cefoxitin 
which showed no variation in MIC values. 
Table 3.3. MIC results of single DD-CPase KOs 
 Amp Vanc Ery RIF Cot Cox Cad Ctx Cap D-cyc 
WT 150-
300 
1.56 0.1 0.155 93.75-
187.52 
20 256 250 100 52.5-
26.25 
∆MSMEG_
1661 
150-
300 
1.56-
3.125 
0.1 0.155 93.75-
187.52 
20 256-
128 
125-
250 
100-
50 
52.5-
26.25 
∆MSMEG_
2433 
150-
300 
3.125 0.1 0.155-
0.31 
93.75-
187.52 
20 256 250 100 52.5-
26.25 
∆MSMEG_
2432 
150-
300 
1.56-
3.125 
0.1 0.31 93.75-
187.52 
20 256-
128 
250 100-
50 
52.5-
26.25 
MIC in µg/mL 
The results are an average of 5 biological repeats 
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4. Discussion 
Mtb is one of the most successful pathogens in human history, with TB disease dating back 
centuries, if not millennia. The rapid emergence of drug resistance is a problem in many 
bacterial organisms and the extensive number of antibiotics to which mycobacteria have 
developed resistance to -  in such quick succession i.e. MDR, XDR and the most recent 
XXDR - is a point of particular concern (Velayati et al., 2009). The disease is further 
exacerbated by the lack of new drug candidates for treating individuals who carry these 
composite forms of drug resistance. Most of this resistance is due to the inherent features 
regarding mutability and adaptation in mycobacteria. As such, a better understanding of key 
aspects in mycobacterial metabolism is required for meaningful impact on TB drug 
development. In this study, we have chosen to study remodelling of the mycobacterial cell 
wall, particularly the PG component.  
The overall cell wall structure of both gram positive and gram negative bacteria is generally 
complex, but the added layers present in the mycobacterial cell wall, such as the mycolic 
acids and arabinogalactan, make the mycobacterial wall vastly more complicated (Hett and 
Rubin, 2008). These unique features make the cell wall an interesting structural target for 
novel drug and vaccine development. Basic physical and metabolic constraints placed on the 
bacterial cell during growth and cell division demand that the cell wall remain dynamic with 
regards to composition and physical structure. The remodelling of various layers in the cell 
wall have garnered recent interest from the perspective of key steps in the cell division 
pathways of many bacterial species (Yang et al., 2012). Our laboratory has principally been 
active in studying the PG layer in the mycobacterial cell wall. The PG layer retains the 
capacity to be restructured by continuous rearrangement of the bonds between side chains to 
create space for the insertion of new PG units and the specialized secretion apparatus/porins 
(Typas et al., 2012). In many organisms the PG layer presents a permeability barrier in the 
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cell, Figure 1.3 (Sobhanifar et al., 2013), and has been of particular interest with regards to 
drug development since its biosynthesis involves a number of both membrane-bound and 
cytoplasmic enzymes which are unique to bacteria, such as the PBPs, the target for β-lactam 
antibiotics (Basu et al., 1992). Bacteria, including mycobacteria, have the ability to bypass or 
inactivate such antibiotics by the production of enzymes such as β-lactamases which 
inactivate β-lactams by a hydrolysis reaction, or by the action of efflux pumps to 
remove/pump out the antibiotic and both these mechanisms work in concert to ensure 
survival of the cell (Livermore, 1995, Jarlier and Nikaido, 1994). 
Remodelling of PG is achieved by a class of enzymes termed hydrolases. This study focused 
specifically on low molecular weight PBPs termed DD-CPases. As stated previously, DD-
CPases act on the terminal D-Ala residue on the pentapeptide side chain of PG and are 
associated with notable genetic  redundancy in bacteria (Hammes and Seidel, 1978). In order 
to assess the function of these genes, single gene knockouts of MSMEG_1661, 
MSMEG_2432 and MSMEG_2433 were created (C. Ealand and B. Kana, unpublished). To 
further study effects of DD-CPase deficiency, we tested the antibiotic susceptibility profiles of 
these single DD-CPase gene knockouts. None of the deletion mutants (∆MSMEG_2432; 
∆MSMEG_2433; ∆MSMEG_1661) displayed an increase in susceptibility to antibiotics 
when compared to WT, Table 3.3. Other studies undertaken with these strains included 
growth kinetics, exposure to cell wall stresses, microscopy and biofilm formation, which 
resulted in the lack of any observable phenotypic abnormalities (Ealand and Kana, 
unpublished). Together, these data suggest that in these deletion mutants, the remaining DD-
CPase-encoding genes play a compensatory role. In order to confirm this, double deletions in 
different combinations, as well as a triple deletion mutant would be required to dissect 
individual versus combinatorial biological roles.  
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The importance of PG remodelling in mycobacteria is demonstrated by the difference in 
abundance of the two types of cross-links between adjacent stem peptides (i.e. 43 and 33 
cross-links), which are observed during different phases of growth (Lavollay et al., 2008). In 
mycobacteria, as in E. coli, there is an increase in the proportion of 33 cross-links at the 
onset of stationary phase, with a subsequent decline in 43 cross-links, (Lavollay et al., 
2008, Hampshire et al., 2004, Lavollay et al., 2011). In E. coli, there is a very low abundance 
of 33 cross-links during exponential growth and it is only at the onset of the lag phase of 
growth that 33 cross-links become apparent, presumably due to nutritional deprivation or 
some other stress response (Templin et al., 1999). This type of cross-link causes the cell to 
increase in rigidity and reduced the susceptibility of the cell wall to PG hydrolases, 
consequently, it has been hypothesized that the organization of stem peptide cross-links in 
this manner may be important for the onset of, or exit from, dormancy in mycobacterial cells 
(Hett and Rubin, 2008).  
Our reasoning for testing the antibiotic susceptibility of DD-CPases deletion strains was 
driven by the published evidence that shows a correlation between LMW PBPs and antibiotic 
resistance. The DacB enzyme from E. coli displays high levels of intrinsic resistance to 
penicillin (Gondre et al., 1973). A PBP5 mutant was more susceptible to antibiotics, 
specifically beta-lactams, which confirmed a role for this protein in the cell’s intrinsic 
resistance to these antibiotics (Sarkar et al., 2010). Another study demonstrated that MICs to 
a number of antibiotics increased as amino acid mutations increased; specifically at positions 
485 (methionine changed to threonine), 499, 629 (Valine substitution) and 466 (serine residue 
added) in PBP5 (Rice et al., 2004). Studies have also shown that during the onset of 
stationary phase in E. coli, pbp3, which encodes a high molecular weight PBP, gene 
expression is down-regulated, and the expression of a gene encoding a low molecular weight 
PBP, pbp6, is up-regulated with an increased amount of 33 cross-links (Boshoff and Barry, 
107 
 
2006, Dougherty and Pucci, 1994). Similarly, a gene encoding a high molecular weight PBP 
in Pseudomonas aeruginosa, pbp3, was also down-regulated and a gene encoding the low 
molecular weight PBP, pbp2, was up-regulated during the onset of stationary phase (Liao and 
Hancock, 1997). It is during stationary phase at which resistance to penicillin-binding drugs 
is high (Boshoff and Barry, 2006). The potential role of LMW PBPs, such as the DD-CPases, 
and changes in PG cross-linking during this stage is potentially interesting when considering 
drug resistance. In organisms such as E. coli and B. subtilis, the different DD-CPases function 
in a growth phase dependant manner as well (described in detail in introduction section 
1.7.3.1) (Ghosh et al., 2008). This adds another layer of complexity to the functionality of 
these genes in the cell. However, the lack of information regarding these genes in 
mycobacteria makes it difficult to ascertain the mechanism of action of the specific DD-
CPases in TB infection. Additionally, the lack of any differential increase or decrease in 
antibiotic susceptibility with the single deletion mutants in this study suggests that the 
remaining LMW PBPs compensate for the loss of a single gene in our mutants. 
DacB and MSMEG_2433 in M. smegmatis 
The rationale for choosing DacB and MSMEG_2433 for further analysis in this study is 
based on the following results from a study currently underway in our laboratory (Kana and 
Ealand, unpublished): (I) Of all the DD-CPases, MSMEG_2433 displays the highest 
homology to E. coli PBP5, with all necessary catalytic residues being conserved, (II) the gene 
encoding MSMEG_2433 is the most highly expressed DD-CPase in M. smegmatis, (III) 
deletion of dacB was not possible – suggesting that it is essential for growth and (IV) 
consistent with this notion, the dacB homologue in M. tuberculosis [Rv3627c - (Machowski 
et al., 2014)] is predicted to be essential from two separate studies (Sassetti et al., 2003, 
Griffin et al., 2011). 
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Of the 4 LMM PBPs in E. coli, the most well-characterized DD-CPase described so far is 
PBP5. Even though PBP5 is dispensable for growth, unlike dacB in M. smegmatis, it has 
been implicated in cell shape as well as resistance to beta-lactam antibiotics (Nelson and 
Young, 2001, Depardieu et al., 2007). Combinatorial PBP5 mutants, that lack other PBPs, 
display morphological abnormalities in cell length and diameter, as well as growth defects 
such as branching and budding, all of which are emphasized as the number of DD-CPase 
deletions increase (Nelson and Young, 2000, Nelson and Young, 2001). Over-expression of 
PBP5 causes defects in cell division, the production of rounded cells and ultimately cell lysis 
(Nelson and Young, 2000). In our study, we also noted morphological changes upon over-
expression of the DacB-rsEGFP fusion, which led to the formation of longer cells.  
Localization of DacB by fluorescence microscopy, with the use of fluorescent tags, revealed 
that this protein mainly localizes to a single cell pole, when over-expressed in M. smegmatis, 
Figures 3.22, 3.26-3.33. This dominance of monopolar localization was present when using 
both Venus and rsEGFP tags, as well as with both the episomal pSE100 and the modified 
integrative pTweety as the shuttle vectors. An interesting observation using the integrative 
vector was that at higher AHT concentrations, bipolar and bipolar with septal localization 
increased significantly to levels equivalent and greater than the monopolar localization. This 
could have been due to a marginal difference in gene expression at these levels, but could not 
be tested as technical difficulties were encountered when attempting to grow cultures 
consistently in liquid media for expression analysis, Figure 3.31D-G. In this study, expression 
of dacB could not be controlled using the ‘Tet on’ system (Guo et al., 2007) as the expression 
data for the pSE100 construct revealed that dacB was over-expressed, relative to wild type, 
under all AHT concentrations. Consequently, we can make no definitive conclusions 
regarding the localization of DacB when expressed at native levels. However, we hypothesize 
that over-expression of DacB, as achieved in this study may provide some insight on the 
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biological role of this protein. Indeed, a similar approach was taken to study PBP localization 
in E. coli and for other cell division proteins in mycobacteria (Nelson and Young, 2001, Kang 
et al., 2008, Maloney et al., 2009). Nelson and Young (2001) showed that E. coli PBP5 needs 
to be not only enzymatically active, but must also be localized to the correct position in order 
to function properly and hypothesized that proper localization could dictate which substrates, 
as well as the amount of substrates on which PBP5 acts. Wag31, a homologue of DivIVA, 
was shown to be essential in mycobacteria and involved in cell division of this organism 
(Cole et al., 1998, Jani et al., 2010, Kang et al., 2008). A mutational study of this gene 
demonstrated cells of abnormal morphologies, i.e. a swelling in one pole – indicative of the 
involvement of Wag31 in PG synthesis at the poles of the cell (Jani et al., 2010, Kang et al., 
2008). Localization confirmed this finding since Wag31 localized to one pole (presumed to 
be the old pole) and less so to the alternate pole, with rare occurrences of septal localization 
(Kang et al., 2008, Meniche et al., 2014), quite similar to the results obtained in this study for 
DacB as well as MSMEG_2433. Wag31 was subsequently shown to interact with, as well as 
co-localize with, ParA (Ginda et al., 2013). 
Cell division proteins in mycobacteria 
ParA and ParB are segregation/partitioning proteins involved in the segregation of the 
chromosome (Fogel and Waldor, 2006). ParA localizes at various positions including polar; 
septal; quarter cell; as well as in a spiral fashion in some cells, whereas ParB indicated 
majority polar localization and occasional septal localization, similar to those observed for 
DacB (Maloney et al., 2009). Co-localization studies of ParA and ParB revealed polar co-
localization, while ParA was shown to co-localize with the nucleoid at the septum, again 
pointing to a role for these proteins in the cell division process (Maloney et al., 2009). 
Wag31and ParA foci were shown to overlap, while the intensity of the ParA localization was 
proportional to that of Wag31 – indicating a dependency between these proteins and re-
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iterating the role of Par proteins in the cell division process of mycobacteria (Kang et al., 
2008, Ginda et al., 2013). 
CrgA is also a mycobacterial cell division protein which interacts with other cell division 
proteins including FtsZ; FtsI; FtsQ and PBPA, and localizes to the cell membrane, poles and 
septum and it was hypothesized that the localization of this protein is dynamic with a 
dependence on the stage of cell division (Plocinski et al., 2013, Plocinski et al., 2012). The 
same study also demonstrated that FtsI localization was dependant on CrgA due to 
localization patterns being altered depending on the amount of CrgA/CrgA levels in the cell 
(Plocinski et al., 2011). PBPA, on the other hand, mainly indicated septal/midcell localization 
(Dasgupta et al., 2006).  
Protein interactions and the cell wall 
The existence and essentiality of protein-protein interactions has been well documented and 
demonstrated to be pivotal for a number of cellular processes. It has been suggested that 
many PBPs act as a complex in order to fully exert their function and for the cell to function 
optimally (Sauvage et al., 2008). To further understand this in mycobacteria, we sought to 
identify DD-CPase-interacting partners by using DacB and MSMEG_2433 as bait proteins in 
a library screen. These studies identified a number of potential interacting partners, with three 
being of particular interest due to the potential of these proteins to form complexes with the 
DD-CPases of interest, i.e. an acyltransferase; an ATP synthase; and a transcriptional 
regulator, Table 3.2. An interesting observation was that both DacB and MSMEG_2433 
displayed the potential to interact with the TetR transcriptional regulator. This points to the 
possibility that both these DD-CPases, and potentially the other PBPs, are under the control of 
the same regulator and may possibly explain the ability of the cell to tolerate deletion of 
CPases with negligible effects on growth and antibiotic susceptibility. The interaction with an 
acyltransferase points to the possibility of a PG hydrolysing complex, as acyltransferase 
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activity is required for  the formation of cross linkages by the transferral or polymerization of 
acyl chains (Rottig and Steinbuchel, 2013). Thus, a possible interaction could involve the 
trimming of the side chains by DacB, which would free the second D-Ala residue on which 
the acyltransferase could act in order to form a cross-link. At this point both these 
explanations are largely speculative and further work is required to confirm any of these 
ideas. Moreover, we can provide no logical explanation at this juncture for the possible 
interaction between DacB and an ATP synthase. Initiation and regulation of cell division are 
energy draining processes but there is no direct evidence from other organisms that PBPs 
regulate energy production in mycobacterial cells. An alternate, more attractive hypothesis is 
that both DacB and the ATP synthase are membrane/periplasmic proteins and the interaction 
between these two proteins in our screen in mainly based on non-specific hydrophobic 
interactions.  
Enzymes involved in the synthesis and breakdown of PG can exert their function only by 
complex formation or by transitory protein interactions (Kana and Mizrahi, 2010). One of the 
most promising potential interacting partners of MSMEG_2433 was the PBP1A/1B (PonA2) 
protein. Sequencing received for two separate clones yielded a hit to PBP1A/1B.This could 
potentially point to a DD-CPase playing a role/ being a part of a synthesis/hydrolysis 
complex, which could work in concert with the previously identified RipA-RpfB-PonA 
complex. Hett et al. (2007) demonstrated that RpfB and RpfE interact with RipA (an 
endopeptidase) and furthermore, both RipA and RpfB co-localized at the septa of dividing 
cells. RipA was also shown to have hydrolase activity against the PG layer and the 
association between RpfB and RipA resulted in enhanced hydrolysis of PG. Depletion of 
RipA results in blockage of normal cell division, abnormal cell morphology, as well as an 
increased susceptibility to antibiotics targeting the cell wall (Hett et al., 2008). In order to 
further study the synergism between RpfB and RipA, studies were carried to establish which 
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other protein/s interact with this complex. PBP1, belonging to the HMW PBP family was 
shown to localize at the septa of dividing cells, with the RipA-RpfB complex. In addition, 
PBP1 was characterized as a bi-functional PG synthesizing enzyme with the ability to inhibit, 
and thus modulate, the RpfB-RipA synergistic interaction (Hett et al., 2010). 
 Such a complex, involving both PG hydrolases as well as PG synthases, is a direct indication 
of the importance of protein-protein interactions to maintain integrity of the cell wall and 
cellular homeostasis. A full understanding of this complex could provide a novel drug target, 
with DD-CPases being a potential target in order to affect the entire cascade of events. A 
model of the interaction of PonA2 and MSMEG_2433 and how it could affect the 
PBP1/RpfB/RipA complex can be proposed from our work, Figure 4.1. The hypothesis 
proposed is that the interaction between MSMEG_2433 and PonA2 occurs during PG 
hydrolysis and this DD-CPase acts in an antagonistic manner to the synthesizing properties of 
PonA2 in order to either ensure efficient PG hydrolysis or prevent the formation of 
inappropriate cross-links. This model was developed by the integration of our data for 
MSMEG_2433 into the model already proposed by Hett et al (2010). 
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Figure 4.1. Model hypothesizing the interaction between MSMEG_2433 and PonA2 in the cell. The hypothesis 
is that MSMEG_2433 interacts with PG synthesizing enzyme PonA2 during PG hydrolysis and would thereby 
prevent this enzyme from synthesizing PG, in order to allow PG hydrolysis to take place efficiently. Adapted 
from Hett et al, 2010. 
 
A number of HMW PBPs have been shown to be involved directly with cell division. In E. 
coli, the enzymes implicated in the formation and action of the divisome are reliant on a 
complexity of interactions involving over 12 proteins in a multi-protein network (Vollmer 
and Bertsche, 2008). These complexes include a number of Fts proteins, as well as amidases 
and PBPs, which all show septal localization. Müller and colleagues (2007) demonstrated  
that FtsN interacts with the existing complex of PBP1B and PBP3 (FtsI), which are PG 
synthases, and hypothesized that FtsN plays a role in modulating this complex, similar to the 
PBP1 modulation described earlier for mycobacteria. Evidence of such complexes is gaining 
interest in mycobacteria as a number of interactions between cell division proteins have been 
identified. (Muller et al., 2007). One such interaction in Mtb is between FtsZ and FtsW and 
FtsW in turn interacting with PBP3 (a HMW PBP) in a trimeric complex, with FtsW as the 
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bridging molecule (Datta et al., 2006). In both M. smegmatis and Mtb, the FtsZ-FtsW 
interaction is essential for Z-ring formation and cell division, with both proteins localizing to 
the septum and FtsW is thus hypothesized to serve as an anchor for FtsZ in order to ensure 
PG synthesis occurs during formation of the septum (Rajagopalan et al., 2005, Datta et al., 
2002). The trimeric complex described is mediated by the proline residues of 
extracytoplasmic loops of FtsW and PBP3 which play a role in PG synthesis (Datta et al., 
2006). In another study CswA (small membrane protein that plays a role in PG synthesis) 
from Mtb, which interacts with CrgA, has been hypothesized to interact with PBPs and 
thereby work in concert to control cell division (Plocinski et al., 2013).  
The potential interacting partners of MSMEG_2433 were of particular interest and in addition 
to PBP1A/1B, our analysis identify other potentially interesting proteins such as a helicase 
and a ssDNA-binding protein, Table 3.2. Co-ordinating cell division with initiation and 
regulation of DNA replication is critical for successful cell division. In this context, our 
identification of components of the DNA replication machinery as potential interacting 
partners for MSMEG_2433 is appealing. Further conclusions in this regards require 
confirmation of these interactions though pull-down assays. Localization of MSMEG_2433 
provided further evidence of the role of this protein in cell division as the protein seemed to 
be either dispersed in a diffused manner in a majority of cells or concentrated to one pole and 
the septum, possibly at the sites of cell elongation and division, Figures 3.37, 3.38 and 3.41. 
An interesting study in E. coli revealed that the branching phenotypes observed in PBP5 
mutants could be related to cell division, in the absence of PBP5 the Z ring is incorrectly 
localized, resulting in increased branching, with this phenotype being exacerbated as the 
other DD-CPases are deleted (Potluri et al., 2012).  
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Concluding remarks 
Taken together, the results from this study highlight an important role for DD-CPases in 
mycobacteria. This is evidenced by polar and polar/septal localization of both DacB and 
MSMEG_2433, a pattern of localization consistent with that seen of other key cell division 
proteins. In addition, these two DD-CPases possibly interact with other key components of the 
cell elongation machinery, such as PonA2, to mediate their action. This understanding could 
be pivotal in the formulation of novel vaccine as well as drug targets. This work is currently 
being progressed by another MSc student in order to confirm these interactions and 
subsequently assess interactions in proteins derived from Mtb. Collectively, these efforts may 
lead to the identification of new drug targets within PG metabolism in mycobacteria.   
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5. Appendices 
Appendix A: Culture media and solutions 
Sterilization of media and solutions were carried out either by filtering or autoclaving at 121 
ºC for 10 min. 
Bacterial growth 
LB: 10 g tryptone, 5 g yeast extract, 10 g NaCl, 1 L sdH2O 
LA: 10 g tryptone, 5 g yeast extract, 10 g NaCl, 1.5 % agarose, 1 L sdH2O 
2 × TY: 20 g tryptone, 10 g yeast extract, 5 g NaCl, 1 L sdH2O 
Middlebrook 7H9: 4.7 g powder, 990 mL sdH2O, 2 mL glycerol, 2 mL 25 % Tween80 (10 
mL Tween80 dissolved in 40 mL sdH2O, filter sterilized), 10 mL 100× glucose-salt (20 g 
glucose, 8.5 g NaCl dissolved in 100 mL sdH2O) 
Middlebrook 7H10: 19 g powder, 990 mL sdH2O, 5 mL glycerol, 10 mL 100× glucose-salt 
YPD broth: 20 g peptone, 10 g yeast extract, 0.003 % adenine hemisulfate (15 mL of filter 
sterilized 0.2 % stock solution), 940 mL sdH2O, 2 % glucose (50 mL of filter sterilized 40 % 
stock solution) 
YPDA: YPD including 20 g agar 
Minimal SD base: 6.7 g yeast nitrogen base without amino acids, 20 g agar, 0.2 g appropriate 
dropout supplement, 950 mL sdH2O, 2 % glucose 
DNA manipulation solutions 
TE buffer: 20 mL EDTA (0.5 M), 10 mL Tris HCl (1 M), sdH2O 
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1 M Tris HCl: 121.1 g Tris, pH adjusted to 8.0 with HCl and made up to 1 L in sdH2O. 
0.5 M EDTA: 93.06 g, pH to 8.0 with NaOH, made up to 500 mL in sdH2O. 
NaCl/CTAB: 10 % N-cetyl-N, N, N-trimethyl ammonium bromide, 4.1 % NaCl, dissolved in 
sdH2O 
TAE buffer: 242g Tris dissolved in 500 mL sdH2O, 100 mL 0.5 M EDTA (pH 8.0), 57.1 mL 
glacial acetic acid, made up to 1 L with sdH2O 
TfbI: 50 mM Manganese chloride, 30 mM potassium acetate, 10 mM calcium chloride, 100 
mM rhubidium chloride, 15 % glycerol, pH adjusted to 5.8 using acetic acid (dilute), made up 
in sdH2O 
TfbII: 10 mM rhubidium chloride, 75 mM calcium chloride, 10 mM MOPS, 15% glycerol, 
pH adjusted to 6.5 with NaOH, made up in sdH2O 
Sodium acetate (3 M): 408.24 g/L sodium acetate dissolved in sdH2O, pH adjusted to 5.2 
with glacial acetic acid 
Solution I: 20 mL 0.5 M glucose, 5 mL 1 M Tris HCl, 4 mL 0.5 M EDTA, made up to 200 
mL with sdH2O 
Solution II: 1 mL 10 M NaOH, 2.5 mL 10 % SDS, made up to 25 mL with sdH2O 
Solution III: 60 mL potassium acetate, 11.5 mL glacial acetic acid, made up to 100 mL with 
sdH2O 
Southern Blot solutions 
SSC (20 ×): 3M NaCl, 0.3M sodium citrate in sdH2O 
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Maleic acid buffer: 116.1 g maleic acid powder, 87. 66 g NaCl, pH 7.5 with NaOH pellets, 
make up to 1 L with sdH2O 
Detection buffer: 0.1 M Tris-HCl, 0.1 M NaCl in sdH2O (pH 9.5) 
Antibody solution (Roche): Dilute 1 in 10 000 in blocking solution 
CSPD (Roche): Disodium 2-chloro-5-(4-methoxyspiro (2-dioxetane-3,2 (2-dioxetane-3,2’-
(5’-chloro)-tricyclo[3.3.1.1. 3, 7. ]decan)-. 4-yl)-1-phenyl phosphate 
Yeast solutions 
PEG/LiAC: 8 mL 50 % PEG 4000, 1 mL 10 × TE buffer, 1 mL 10 × LiAC 
LiAC (10 ×): 1 M lithium acetate, pH adjusted to 7.5 with acetic acid (dilute) 
X-α-Gal: 20 mg/mL X-α-Gal dissolved in DMF 
Appendix B: Molecular weight Markers
 
DNA  molecular 
weight marker II
DNA  molecular 
weight marker III
DNA  molecular 
weight marker IV
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Appendix C: Primers 
Table C 1: Primers used to check site-specific integration of pMC1s 
Primer Sequence 5’- 3’ Amplicon 
attL2 CTTGGATCCTCCCGCTGCGC  
282 bp attBS1 ACGTGGCGGTCCCTACCG  
attBS2 ACAGGATTTGAACCTGCGGC  
320 bp attL4 AATTCTTGCAGACCCCTGGA 
 
Appendix D: Library and Yeast Mating 
Library Transformation Efficiency 
Transformation efficiency (TE) = 
                       
               
             
Yeast Mating Zygote formation  
 
Figure D1: Image of zygote formation during yeast mating experiment, indicating the occurrence of mating of 
the yeast strains. Image was taken using a light microscope at 40 × magnification. 
 
 
 
dacB 2433
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Calculations 
Viability  = No. of colonies (CFU) × Resuspension volume (mL) × Plating volume 
(mL)      × Dilution factor 
Mating efficiency  = 
                        
                                 
       
   = % diploids 
DacB: MSMEG_2433: 
Prey viability = 207 × 12 × 10 × 1000 
  = 2.5 × 10
7
 CFU/mL 
Prey viability = 218 × 12 × 10 × 1000 
  = 2.6 × 10
7
 CFU/mL 
Viability of diploids = 22 × 12 × 10 × 100 
           = 2.6 × 10
5
 CFU/mL 
Viability of diploids = 20 × 12 × 10 × 100 
           = 2.4 × 10
5
 CFU/mL 
Mating efficiency = 
         
          
       
   = 1.0 % 
Mating efficiency = 
          
          
       
   = 1.0 % 
 
Appendix E: PCR confirmation of clones  
 
Figure  E2: PCR of pSEdacB-mCherry clones 
from M. smegmatis colony boil. Lane 1: M. 
smegmatis clone C5, Lane 2: M. smegmatis 
clone C8, Lane 3: Marker IV. Expected size of 
PCR band: 2126bp
1  2 3
2126 bp
1            2             3
Figure  E1: PCR of pSE2433-rsEGFP and 
pSE2433-Venus clones from M. smegmatis colony 
boil. Lane 1: Marker IV, Lane 2: M. smegmatis 
pSE100::2433_rseGFPclone C8, Lane 3: M. 
smegmatis pSE2433-Venus clone C8. Expected 
band: 1616bp
1616 bp
1627 bp
1        2        3
Figure E3: PCR of pSEdacB-Venus clone 
from M. smegmatis colony boil. Lane 1: 
Marker IV, Lane 2: M. smegmatis clone 
C3(i), Lane 3: M. smegmatis clone C3(ii). 
Expected band: 2183bp
2183 bp
1                  2         3
Figure  E4: PCR of pSEdacB-rseGFP clones from 
M. smegmatis colony boil. Lane 1: Marker III, 
Lane 2: M. smegmatis clone C1, Lane 3: M. 
smegmatis clone C2. Expected band: 2172bp
21226
5148
1584
831
4268
3530
2027
1904
2172 bp
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Appendix F: Repeated restriction digests 
 
Figure F1: Repeated restriction digest of pGBKdacB and pGBK2433. (A) BamHI + NdeI digest of pGBKdacB. 
[Lane 1] Roche marker IV, [Lane 2] uncut pGBKdacB, [Lane 3] BamHI + NdeI. (B) HinDIII digest of 
pGBK2433. [Lane 1] Roche marker IV, [Lane 2] uncut pGBK2433, [Lane 3] HinDIII. 
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Figure  E4: PCR of pSEdacB-rseGFP clones from 
M. smegmatis colony boil. Lane 1: Marker III, 
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